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In this dissertation, we investigate two problems: (1) the problem of establishing
a “gold standard” for developing and optimizing multicomponent interventions that
allows for valid inference about individual components and their interactions (Ch.
III, IV); and (2) the problem of non-regularity that arises in the estimation of optimal
dynamic treatment regimes from longitudinal data on patients (Ch. V). Both these
methodological research directions are motivated by our involvement in the design
and analysis of a smoking cessation trial [88] conducted by the Center for Health
Communications Research (CHCR) at the University of Michigan; a description of
this trial is given in Chapter II.
1.1 Designing Multicomponent Intervention Trials
The first problem investigated in this dissertation is the design of multicomponent
intervention trials. Multicomponent or complex interventions are increasingly being
used in many health domains, e.g. AIDS [41], cardiovascular diseases [28], depres-
sion [105], diabetes [65], drug abuse [68], gerontology [1], obesity [8], and smoking
cessation [88]. While some components may involve a medication, many components
are behavioral, implementation, or delivery factors [28, 105, 88]. As has been rec-
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ognized in the literature [1, 18, 39, 86, 103], development and evaluation of these
multicomponent interventions pose additional design challenges over those of single-
component interventions, and these challenges tend to be addressed poorly by the
standard two-group randomized controlled trials. More specifically, such two-group
randomized trials do not provide direct information on which components are active,
whether they have been set at optimal levels, and whether any of the components
interact.
The classical approach and its problem
The classical approach (sometimes called the treatment package strategy) to de-
velop multicomponent interventions [47, 103, 102] consists of constructing a likely
best intervention package based primarily on prior empirical research, readings of
the literature, theory and clinical experience. This intervention is then evaluated in
a standard randomized controlled trial. In the course of this trial, data are collected
not only on the outcomes of primary interest but also on other variables so as to
enable quasi-experimental, non-experimental and post hoc analyses [68, 1, 96, 97]
aimed at shedding light on what worked well and what might need improvement.
Examples of such analyses include regressing outcomes on naturally occurring vari-
ation in participation, compliance, or implementation fidelity. Other observational
analyses include theory-based mediational analyses [103, 106]. The intervention is
often refined based on the findings of these analyses, and then the refined version is
tested in another two-group randomized trial. Sometimes several such iterations are
performed to refine the multicomponent intervention. Thus the questions regarding
individual components and their interactions are answered by observational analyses.
The main problem with this approach is that it depends heavily on the non-
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experimental, observational analyses. As is well-known [44, 72, 74], findings that
are not based on randomization are contaminated by the likely presence of unknown
confounders (e.g. the variables that affect both the receipt of an intervention com-
ponent and the outcome). As a consequence, the effects of individual components
and interactions may be misinterpreted resulting in a suboptimal intervention.
1.1.1 Multiphase Optimization Strategy (MOST)
To address the above problem with the classical approach, an experimental ap-
proach called the Multiphase Optimization Strategy (MOST) was proposed by Collins
et al. [25], and further developed and illustrated by Nair et al. [62]. Examples of suc-
cessful implementation of MOST include the works of Nair et al. [62] in breast cancer
prevention and Strecher et al. [88] in smoking cessation. A description of this smoking
cessation trial can be found in Chapter II.
The MOST approach includes additional evidentiary steps along with the two-
group randomized trial as part of the process of building and evaluating multicompo-
nent interventions. MOST consists of two evidentiary phases to precede and inform
a confirmatory two-group randomized trial. The first phase, called screening, con-
sists of randomized experimentation designed to obtain estimates of the effects of
individual components and selected interactions between components. The resulting
experimental evidence provides the basis for preliminary decisions about which com-
ponents to select for inclusion. A second phase of additional experimentation, called
refining (sometimes called follow-up study), is used to identify the best level of one
or more components, to investigate interactions between components, and to resolve
any other remaining questions. The final confirmatory two-group trial is sometimes
referred to as the confirming phase of the MOST approach. Information on cost and
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burden can be collected in the course of experimentation and included when deci-
sions are made concerning choices of components and/or levels. Conclusions drawn
from the results of the screening and refining phases form the basis for specification
of an intervention (to be tested in the confirmatory trial) that consists of a set of
active components implemented at levels selected to maximize efficacy, effectiveness,
and/or cost-effectiveness.
Even though the screening and refining studies precede a confirmatory random-
ized trial of the “optimized” multicomponent intervention vs. control, they are not
pilot studies by most widely accepted definitions [76, 48, 98]. According to these def-
initions, a pilot study is typically conducted to assess the feasibility (of recruitment,
intervention delivery, data collection) of a full-blown randomized trial; indeed pilot
studies may be conducted with little regard for power, and may not even involve
randomization. By contrast, screening and refining studies as described by Collins
et al. [25] are adequately powered randomized trials intended to assist in refining and
optimizing multicomponent interventions and may themselves be preceded by pilot
studies to assess feasibility.
1.1.2 MOST and Factorial Designs
Full and fractional factorial designs (FFD) that have been extensively used in
agricultural and industrial experiments for many decades [108, 36, 9, 107] can be
used efficiently in the screening phase of MOST. Nair et al. [62] described the use of
FFDs within the MOST framework in two behavioral intervention studies, e.g. Guide
to Decide and Project Quit. One goal of the current dissertation is to establish FFDs
within the MOST framework as the “gold standard” for developing multicomponent
interventions. Below we describe how we will proceed to achieve this goal.
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Justifying the use of FFDs in screening studies
Even though the use of FFDs in the screening phase of MOST was described by
earlier authors [25, 62, 88], there exists a tremendous amount of controversy regarding
the use of factorial designs in the clinical and behavioral intervention trials literature
[16, 103, 67]. Factorial designs have been assessed by biostatisticians in the context
of confirmatory medication trials; the objective has been to evaluate the usefulness
of a combined medication over a single medication. In this context, the criticisms of
factorial designs relate to cost, feasibility, ethics, toxicity of combined medications,
interpretation of main effects in presence of active interactions, and power to detect
interactions. In Chapter III of the current dissertation, which is based on a recent
paper [19], we describe how one can address these common criticisms (and some
misconceptions) regarding the use of (fractional) factorial designs in the context of
screening trials (which is different from evaluation or confirmatory trials) for devel-
oping multicomponent interventions. To the best of our knowledge, addressing the
criticisms against FFDs in the context of the MOST framework (screening phase)
has not been done before.
Additionally in Chapter III, we provide an operationalization of screening studies
using FFDs for up to six components. We also present some hypothetical examples
of follow-up studies, as well as the follow-up study design of Project Quit.
Comparing MOST with the classical approach in a simulation study
MOST is a relatively new experimental framework to a lot of behavioral inter-
vention scientists. We feel that an illustrative simulation study, which shows that
MOST performs better than the classical approach under a lot of simulated scenarios
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that mimic some of the well-known characteristics of real studies, has the promise
of disseminating this framework further. In Chapter IV, which is based on a recent
paper [22], we present such an illustrative simulation study that provides a head-to-
head comparison of MOST (implemented using FFDs) with the classical approach
(two-group randomized trial followed by observational analyses). This comparison is
based on a generative model that involves five intervention components, varying lev-
els of adherence to each component, a negative interaction between two components,
an unknown confounder, and a continuous outcome variable. The simulation results
show that under a lot of different scenarios (e.g. varying effect size and sample size),
the MOST approach (implemented using FFDs) outperform the classical approach in
terms of various criteria, e.g. optimizing the mean outcome of the final intervention
and identifying the best intervention. This chapter, we believe, will strengthen the
case for FFDs within the MOST framework as the “gold standard” for developing
multicomponent interventions.
1.2 Dynamic Treatment Regimes
The second problem studied in this dissertation is the phenomenon of non-regularity
arising in the estimation of the optimal dynamic treatment regimes (DTR). DTRs
are useful tools in treating chronic disorders (e.g., depression, schizophrenia, sub-
stance abuse, HIV infection etc.). In order to manage the waxing and waning nature
of these disorders, clinicians typically treat patients in multiple stages, adapting
the treatment type and dosage to the ongoing measures of an individual patient’s
response, burden, adherence to prior treatment, side effects, and preference. Prac-
tice guidelines for clinicians offer treatment recommendations, but they often rely
7
heavily on expert opinion because of limited direct scientific evidence. DTRs rep-
resent a paradigm to operationalize this adaptive clinical practice, and thereby to
improve it. A DTR is a sequence of (treatment) decision rules, one per stage. Each
decision rule takes a patient’s treatment and covariate history as input, and out-
puts a recommended treatment. To make these treatment rules “evidence-based”,
one has to estimate them from longitudinal data on patients in a principled way.
Data for estimating DTRs come from multi-stage studies – either an observational
longitudinal study or a sequential multiple assignment randomized trial (SMART)
[49, 50, 32, 58, 59]. In SMART designs, each patient is followed through stages of
treatment and at each stage the patient is randomized to one of the possible treat-
ment options. Experimental designs similar to SMART have been implemented in
the treatments of schizophrenia [81], depression [78] and cancer [93, 99]. Below we
briefly discuss the framework of multi-stage studies.
1.2.1 The Framework of Multi-stage Studies
For simplicity, let us focus on studies with only two stages of treatment. Longi-
tudinal data on a single patient are given by the trajectory
{O1, A1, O2, A2, O3},
where Oj (j = 1, 2) denotes the covariates observed prior to treatment at the begin-
ning of the j-th stage, O3 is the observation at the end of stage 2, and Aj (j = 1, 2)
is the “action” or treatment assigned at the j-th stage subsequent to observing Oj.
Define history available at each stage as: H1 = O1, H2 = (O1, A1, O2). The study
can have either a single primary outcome Y observed at the end of stage 2, or two
outcomes Y1, Y2 observed at the two stages (and the interest is in Y1 +Y2). Note that
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the case of a single outcome Y observed at the end can be viewed as a case with
Y1 ≡ 0 and Y2 = Y . We assume that the outcomes are specified summaries of ob-
servations and treatments, i.e., Y1 = f1(O1, A1, O2) and Y2 = f2(O1, A1, O2, A2, O3),
with known functions f1, f2. In this simple framework, a DTR is a two-component
vector of decision rules, say (d1, d2), with dj(Hj) ∈ Aj, where Aj represents the set
of possible treatments at the j-th stage. An example of such a decision rule can be:
“stop treatment if ψT Hj > 0, otherwise maintain on current treatment”, where ψ is
a vector of parameters. A DTR is called optimal if it leads to a maximal mean Y
(or, maximal mean sum of Yj’s). The goal is to construct optimal DTRs, e.g. by
estimating the ψ’s featuring in the optimal DTR. Note that this simple framework
of two stages can be generalized to more than two stages. Below we present two
concrete examples.
Two-stage Smoking Cessation Trial (Strecher et al., 2008)
We present a randomized, two-stage, longitudinal, internet-based smoking ces-
sation and relapse prevention study. We will treat this example in great detail in
Chapters II and V; here is only a gentle overview. The stage 1 of this study (Project
Quit) was conducted to find an optimal multicomponent behavioral intervention to
help adult smokers quit smoking; and the stage 2 (Forever Free) was a follow-on
study to help those (among the participants of Project Quit) who already quit stay
quit, and help those who failed at the previous stage with a second chance. Here O1
consists of baseline variables (e.g., motivation, self-efficacy, education), O2 (also Y1)
consists of several stage 1 outcomes (e.g., quit status, reduction in the average num-
ber of cigarettes smoked per day, number of months not smoked during the study
period – all measured at 6 months from the baseline), and O3 (also Y2) consists
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of the same outcome variables measured at stage 2 (12 months from the baseline).
A1 and A2 represent the behavioral interventions given at stages 1 and 2 respectively.
Two-stage Cancer Trials (Wahed and Tsiatis, 2004)
In a two-stage design for cancer trials, patients are often treated initially with
an induction therapy (powerful chemotherapy to induce remission of disease) fol-
lowed by (at some later time-point) either some maintenance therapy to intensify
or augment the effects of induction therapy, if the patient “responds” (shows sign
of remission), or some other induction therapy (switch of treatment), if the patient
does not respond to the initial therapy. Here O1 stands for pre-treatment variables
(e.g., age, sex, ethnicity etc.), A1 is the induction therapy at the first stage, O2 is
whether or not the patient “responds” to initial induction therapy, A2 is either the
maintenance therapy (if the patient responds) or the new induction therapy at the
second stage (if the patient does not respond), and O3 (also the outcome Y ) is the
disease-free survival time.
1.2.2 Estimation and Inference
Methodological developments for estimating DTRs took place in recent times.
Thall et al. [93, 94, 95] considered likelihood-based methods (both frequentist and
Bayesian) for estimating DTRs, primarily in the context of cancer. Murphy et al.
[60] provided a method of estimation for the mean outcome that would have been ob-
served had the study population followed a particular DTR, based on observational
longitudinal data and under the assumption of sequential randomization. Parmi-
giani [64] considered modeling medical decisions by Bayesian approaches. Murphy
[56] provided a semi-parametric regret modeling methodology, sometimes called A-
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Learning [7]. An efficient version of this method was provided by Robins [71]. A good
discussion of the relationship between these methods can be found in Moodie et al.
[55]. Other methods for estimating DTRs include the semi-parametric methods due
to Lunceford et al. [51] and Wahed and Tsiatis [99, 100] in the context of two-stage
cancer trials, with survival distribution as the primary outcome. Rosthoj et al. [73]
considered a case study based on Murphy’s [56] methodology using observational
data. The problem of inference for the parameters of the optimal DTR was studied
by [71].
Non-regularity
Robins [71] identified the problem of non-regularity in the context of estimating
optimal DTRs. As discussed by Robins, the treatment effect parameters at any
stage prior to the last can be non-regular under certain longitudinal distributions
of the data which he called exceptional laws. By non-regularity, we mean that the
asymptotic distribution of the estimator of the treatment effect parameter does not
converge uniformly over the parameter space. This phenomenon of non-regularity
causes bias in estimation, and leads to poor frequentist properties (e.g. coverage
rates) of the confidence intervals. Recently Moodie and Richardson [54] provided a
method called Zeroing Instead of Plugging In (ZIPI) for correcting the bias in the
estimation of the optimal DTRs resulting under exceptional laws.
In Chapter V of this dissertation, we illustrate the problem of non-regularity using
a method of estimation called Q-learning [101, 90, 58]. This method, like Robins’
g-estimation of optimal structural nested mean models, suffers from non-regularity –
the common reason being an underlying non-smooth maximization operation. We
show that under simple conditions, Q-learning is equivalent to an inefficient version
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of Robins’ method; however Q-learning is simpler to visualize. To address non-
regularity, we propose a new estimator called the soft-threshold estimator within the
framework of Q-learning, and compare it with other available estimation techniques
that attempt to address this problem (including the ZIPI or hard-threshold estima-
tor) via extensive simulations. The soft-threshold estimator falls within the class of
shrinkage estimators, and the tuning parameter governing the shrinkage is specified
by an empirical Bayes formulation of the problem. The content of this chapter is
based on a recent paper by Chakraborty et al. [20].
1.2.3 Dynamic Treatment Regimes and Multicomponent Interventions
Note that while developing a DTR, one has to decide on a number of questions,
e.g., when to start treatment, which treatment type and/or dosage to start with,
when to step up (augment) treatment and to which, when to step down treatment
to maintenance or monitoring therapy, and what information to use to make the
above decisions. Thus a DTR can be viewed as a possibly high-dimensional mul-
ticomponent intervention. Hence a series of developmental or screening trials may
be necessary before conducting a confirmatory trial to evaluate a DTR in compar-
ison with a standard alternative treatment (control). Hence the MOST framework
in general, and FFDs in particular, can provide useful tools in the development of
DTRs. This conceptual connection, in a way, ties the two broad problems considered
in this dissertation together.
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1.3 Outline
In the present chapter, we have discussed the MOST framework for developing
multicomponent interventions. We have also introduced the general concept of DTRs
and the phenomenon of non-regularity that arises in the estimation of DTRs. In the
subsequent chapters, we will build on this background and discuss specific research
done along these lines. In Chapter II, we give a detailed description of a study
on smoking cessation [88]. We use the first stage of this study (Project Quit) as
an example where MOST (using FFDs) was successfully implemented. Also in this
smoking cessation study, the problem of estimating the optimal DTR arises naturally.
We use this as a motivating example for the methodology considered in Chapter V.
Chapter III is devoted primarily to addressing the concerns and criticisms against
FFDs in the context of the screening phase of MOST. Here we also provide an
operationalization of screening trials using FFDs and some discussion on follow-up
studies. Chapter IV provides a head-to-head comparison between two competing
approaches to develop multicomponent interventions, e.g., (a) MOST using FFDs,
and (b) traditional two-group randomized trial followed by non-experimental post
hoc analysis, using a complex simulation study. The simulation study shows how
approach (a) outperforms approach (b) in most scenarios.
In chapter V, we present the problem of non-regularity arising in the estimation
of optimal DTRs in full detail. Here we derive Q-learning as an inefficient version
of Robins’ [71] method of estimation in structural nested mean models (SNMM). We
propose the soft-threshold estimator to address non-regularity, and derive it as the
empirical Bayes estimator under a hierarchical Bayesian model. We also present a
comprehensive simulation study to compare different methods in regular as well as
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non-regular settings. Finally, we provide two separate analyses (one is the complete-
case analysis, the other using multiple imputation) of the smoking cessation data to
illustrate the developed methodology.
In chapter VI, we discuss possible extensions and future work. With reference to
the work on designing multicomponent intervention trials, future research consists of
exploring the area of follow-up studies with more rigor. Future research directions
related to DTRs include extending the proposed soft-threshold method to the setting
of more than two treatment options per stage, and devising a consistent bootstrap
procedure for using in non-regular settings. We briefly outline our plans to explore
these in future.
CHAPTER II
The Motivating Study on Smoking Cessation
In this chapter, we will describe the Project Quit and the Forever Free studies,
conducted by the Center for Health Communications Research (CHCR) at the Uni-
versity of Michigan. Together they provide a setting where the problem of estimating
optimal dynamic treatment regime arises naturally; we want to use this setting as
an example to motivate the methods proposed later in this thesis. The Project Quit
study also exemplifies a successful implementation of the MOST framework and the
use of fractional factorial designs (FFDs) therein.
2.1 Project Quit Study
Project Quit is a web-based smoking cessation program developed by researchers
at the Center for Health Communications Research of the University of Michigan,
Ann Arbor, and two health maintenance organizations (HMO), e.g. the Group
Health Cooperative (GHC), Seattle, and the Henry Ford Health System (HFHS),
Detroit. The funding for this study was provided by the National Cancer Insti-
tute (NCI). The subjects of this study were recruited from the population of adult
patients of two health maintenance organizations (HMOs), e.g. GHC and HFHS,
associated with NCI’s Cancer Research Network (CRN). This population provided
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a broad representation of ethnicity, gender, age, health status, and geography. The
collaboration allowed the researchers to test some cutting-edge web-based technol-
ogy in a real-world environment that has the infrastructure for both evaluating and
disseminating population-based cancer prevention and control programs. This study
used the MOST framework (implemented using FFDs) to screen and identify the
effects of some psycho-social and communication factors (treatment components) in-
fluencing smoking cessation.
2.1.1 Factors and Study Design
An FFD was used to screen and identify the factors influencing cessation from a
set of potentially active factors of a web-based cessation induction intervention. Six
factors listed below, each at two levels, were considered originally.
Table 2.1: Project Quit Factors and Their Levels
Factor High Level (+) Low Level (−)
Outcome Expectations High Tailoring Depth Low Tailoring Depth
Efficacy Expectations High Tailoring Depth Low Tailoring Depth
Success Stories High Tailoring Depth Low Tailoring Depth
Message Source High Personalization Low Personalization
Message Framing Gain Framing Loss Framing
Message Exposure Single Multiple
The originally planned design was a 32-arm FFD. However, due to an implemen-
tation error, a decision was made later to drop the factor Message Framing from the
study, and subsequently fold the design to have 16 treatment arms. Details of the
study design can be found in [88] and also in chapter III.
The factors of this study were examined across a set of individual characteristics.
These characteristics were baseline level of motivation and self-efficacy (on a 10-point
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scale), barriers (e.g., fear of weight gain, smoking habit of spouse, prevalence of
friends and co-workers who smoke etc.), need for cognition (an individual’s tendency
to engage in and enjoy effortful cognitive endeavors), health locus of control (refers
to the belief that behaviors are causally related to outcomes, or are determined by
external factors such as luck, chance etc.), and socio-demographic (e.g., age, gender,
education, ethnicity) and health status characteristics (e.g., hypertension, diabetes,
heart disease etc.). Interactions of some of these subject characteristics with the
factors were studied.
2.1.2 Data Collection
During the subject recruitment phase, an introductory recruitment letter was sent
to individuals randomly chosen from the study population. The letter explained the
project (describing the research, its purpose, and its risks and benefits) and asked
individuals to voluntarily participate in this project by visiting the web site
http://www.projectquit.org
to complete an electronic consent form and eligibility questionnaire. Subjects were
eligible for the study if they satisfied the following criteria:
1. They were between 21 and 70 years of age.
2. They were assigned to a physician panel at GHC or HFHS as of January 1,
2003.
3. They were capable of communicating in English.
4. They were current smokers, defined as: they had smoked at least 100 cigarettes
in their lifetime, they reported smoking in the last seven days, and they reported
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smoking at least 10 cigarettes per day during the time of this survey.
5. They were not enrolled in any other smoking cessation program, or not using
pharmacological therapy for smoking cessation.
6. They had access to the internet and had an email account that they used to use
at least twice a week.
All eligible individuals who agreed to participate in the study completed a baseline
survey, selected a quit date between two and four weeks from the date of the baseline
survey completion date, and were randomized to one of the treatment arms.
The baseline questionnaire assessed the subject’s smoking history, psychosocial,
health, and demographic characteristics relevant to smoking cessation. Randomiza-
tion was done automatically by the computer and was invisible to the subject. Data
from the baseline survey were used to generate the experimental web site condition
to which the subject was randomly assigned. Subjects were encouraged to complete
the baseline questionnaire through the use of periodic email reminders. Follow-up
assessment was performed six months after initial login. At this time, the subject
was called by a trained telephone interviewer using a computer-assisted telephone
interview (CATI).
2.1.3 Outcome Measures
The primary outcome in the Project Quit study was the seven-day point-prevalence
in smoking cessation (binary) at six months following the baseline assessment. Dur-
ing the 6-month evaluation survey, each subject was asked if s/he had smoked any
cigarettes, even a puff, in the last seven days. A subject answering “yes” to this
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question was marked as a smoker.
A criticism of the above outcome measure is that it is only based on a subject’s
smoking status in last seven days, as opposed to last 6 months. However, data
on some secondary outcomes such as number of months not smoked by a subject,
changes in the number of cigarettes smoked per day and number of quit attempts in
the past 6 months were also collected.
2.2 Forever Free Study
Forever Free is a web-based smoking cessation and relapse prevention program
developed as a follow-on program to the Project Quit study. The funding for this
developmental project was provided by the University of Michigan. The goal of this
study was to help the participants of the Project Quit study – to help the quitters
stay quit and to help the non-quitters continue the quitting process. Subjects of this
study were recruited from the participants of the Project Quit study. During the six-
month CATI follow-up to Project Quit treatment assignment, the participants were
asked if they wanted to participate in the Forever Free program and if they would
mind being contacted about it. The subjects who consented on the phone, received
invitation email for participating in Forever Free. Then the subjects gave their con-
sents online by visiting the Forever Free web site. The subjects who consented were
subsequently randomized to one of the 5 treatment arms discussed below. Subjects
were blocked by their quit status (based on their seven-day point prevalence in the
Project Quit study, HMO membership (GHC vs. HFHS), and exposure in Project
Quit (single or multiple).
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2.2.1 Factors and Study Design
In the Forever Free study, two factors, each at two levels, gave rise to a 2× 2 full
factorial design. Additionally, a control arm was considered for certain comparisons
of interest. Thus a total of 5 treatment arms were constructed. If n be the total
number of participants in this study, then the planned sample size for the control
arm was n
3
, while each of the other 4 arms were planned to have a sample size of n
6
.
Table 2.2: Two Forever Free Factors and Their Levels
Factor High Level (+) Low Level (−)
Tailoring Locus Expert System User Navigation
Graphic Content Graphic Rich Graphic Poor
The intervention primarily consisted of the contents of 8 smoking relapse pre-
vention booklets, written by Dr. Thomas Brandon, and available on the NCI web
site:
http://www.smokefree.gov/pdf.html
The wordings of these booklets were adjusted to reflect that a participant had or had
not quit (according to Project Quit outcome). Each of these booklets is about han-
dling a particular situation when a subject may feel the urge to smoke, e.g., stress,
loneliness etc. The factors determined how these booklets were presented to the
subjects. For example, with reference to the second factor, the graphic poor version
(lower level) included simple clip-art style graphics found in the PDF version of the
booklets, while the graphic rich version (higher level) included enhanced graphics
that better communicated the ideas in the text. Thus there were four versions of
each booklet, viz., graphic rich for those who have quit smoking, graphic poor for
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those who have quit smoking, graphic rich for those who have not quit smoking, and
graphic poor for those who have not quit smoking. On the other hand, the first fac-
tor, tailoring locus, determined whether or not the choice of booklets were tailored
to a particular subject’s needs. In lower level of this factor (user navigation), the
subjects were presented with an web page with links to all the 8 booklets, and they
had to self-select which ones they wanted to review by clicking on appropriate links.
In higher level of this factor (expert system), although the subjects had access to all
the 8 booklets, they were advised to review up to 3 booklets by the “expert”, based
on their answers to a previous questionnaire. Subjects in the control arm did not
get any of these booklets; they only received an encouraging message to quit smoking.
2.2.2 Data Collection
Subjects were invited to participate in this follow-on study as part of the Project
Quit six-month CATI follow-up. They were sent an email reminder with a link to
the site
http://www.projectquit.org/foreverfree
approximately seven days after completing the CATI interview. Information col-
lected in the six-month CATI follow-up were used to tailor the selection of the ap-
propriate booklet for participants in the expert system cells. If a participant failed to
log in to the web site, they were sent email reminders at 1, 3, and 5 days reminding
them to visit the web site to enroll in the follow-on study.
All subjects were sent an email reminder at three months (post enrollment in the
follow-on study) asking them to return to the web site and complete a short survey.
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If a participant failed to visit the web site to complete the survey, they were sent
email reminders at 1, 3, and 5 days asking them to visit the web site to do the three-
month survey. If a subject started the three-month survey but failed to complete it,
they were sent email reminders at 1, 3, and 5 days after they started the three-month
survey asking them to return and complete the three-month survey.
All subjects were sent an email reminder at six months (post enrollment in the
follow-on study) asking them to return to the web site and complete the six-month
survey. If a subject failed to visit the web site to complete the survey, they were
sent email reminders at 1, 3, and 5 days asking them to visit the web site to do
the six-month survey. If a participant started the six-month survey but failed to
complete it, they were sent email reminders at 1, 3, and 5 days after they started the
six-month survey asking them to return to the web site and complete the six-month
survey. Subjects that did not complete the six-month survey on the web were mailed
a copy of the survey to complete. After six months (post enrollment in the follow-on
study), subjects were redirected to the NCI web site to view the booklets. Although
both three-month and six-month data were collected, we will focus on the six-month
data only.
2.2.3 Outcome Measures
The primary outcome in the Forever Free study was seven-day point-prevalence
in smoking cessation, which is binary. At 3-month or 6-month survey, each subject
was asked if s/he had smoked even a single cigarette during the last seven days. A
subject answering “yes” to this question was marked as a smoker.
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As before, secondary outcomes included how many months a subject has been off
cigarettes, changes in the number of cigarettes smoked per day, and number of quit
attempts.
2.3 Dynamic Treatment Regime Framework
Having described the study on smoking cessation, let us now identify the set-up for
estimating a dynamic treatment regime. Note that, in the combined Project Quit –
Forever Free study, two randomizations were done, one is the Project Quit treatment
assignment (1 out of 16), the other is the Forever Free treatment assignment (1 out
of 5). So these are the two time-points in the dynamic treatment regime framework.
Ideally, for each subject, we have a longitudinal record of the form
{O1, A1, O2, A2, O3},
where O1 represents baseline subject characteristics, A1 is the Project Quit treatment
arm the subject was assigned to, O2 stands for the subject characteristics and out-
comes measured during 6-month CATI follow-up, A2 is the Forever Free treatment
arm the subject was assigned to, and O3 stands for the subject characteristics and
outcomes measured during 6-month follow-up from Forever Free treatment assign-
ment. History at each stage can be defined as a suitable lower dimensional summary
of previous O’s and A’s. The primary outcome at each stage is the (binary) seven-
day point prevalence in smoking cessation. Some secondary outcomes (e.g., how long
a subject has been off cigarettes) are also available.
The goal in the present problem is to estimate the optimal dynamic treatment
regime (sequence of individualized treatments) that is most effective in smoking ces-
23
sation – the one that maximizes the combined outcome over the two stages, and also
to attach measures of confidence (statistical inference).
For all subsequent analyses in this thesis, we will collapse the 4 different versions
of the Forever Free intervention (due to little difference between them) to form a
single treatment arm and compare it with the control arm.
2.3.1 Preliminary Descriptive Numbers
Here we present some preliminary descriptive numbers relating to the data. As
we see below, a lot of subjects from Project Quit decided not to continue to Forever
Free (only 479 out of 1848 subjects decided to continue); this step was part of the
protocol, and hence these subjects are not considered as drop-out. However note that
only 1401 out of 1848 stage-1 subjects completed the six-month CATI survey; these
1401 subjects are treated as complete cases and would be considered in complete-case
analysis in chapter V; the remaining 447 subjects are considered drop-outs in the
stage-1 data. Similarly, 281 subjects who completed the stage-2 six-month survey
are considered as complete cases in the complete-case analysis in chapter V; the
remaining 479 − 281 = 198 are considered drop-outs in the stage-2 data. Also note
that these numbers will change as we vary the outcome under consideration; here we
focus on the primary outcome (quit status) only.
Table 2.3: Descriptive Numbers about the Smoking Cessation Data
Subjects at different stages of the study n
Subjects who were assigned to a Project Quit treatment arm 1848
Subjects for whom Project Quit 6-month primary outcome is available 1401
Subjects who were assigned to a Forever Free treatment arm 479
Subjects for whom Forever Free 6-month primary outcome is available 281
24
Descriptive checks revealed that drop-out was more or less uniform across the
different treatment arms in both stages. In chapter V, we will also present a refined
analysis using multiple imputation (as is well-known, complete case analysis often
gives biased results).
CHAPTER III
Developing Multicomponent Interventions using Fractional
Factorial Designs
Multicomponent interventions composed of behavioral, delivery, or implementa-
tion factors in addition to medications are becoming increasingly common in health
sciences. A natural experimental approach to developing and refining such multi-
component interventions is to start with a large number of potential components and
screen out the least active ones (e.g. the screening phase of MOST). Factorial de-
signs can be used efficiently in this endeavor. In this chapter, we address the common
criticisms and misconceptions regarding the use of factorial designs in the context of
screening studies. We also provide an operationalization of screening studies. As an
example we consider the use of a screening study in the development of a multicom-
ponent smoking cessation intervention. Simulation results are provided to support
the discussions.
3.1 Introduction
As discussed in Chapter I, multicomponent interventions composed of behav-
ioral, delivery, or implementation factors in addition to medications are becoming
increasingly common in health sciences. As has been recognized in the literature
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[1, 18, 39, 86, 103], development and evaluation of these multicomponent interven-
tions pose additional design challenges over those of single-component interventions,
and these challenges tend to be addressed poorly by the standard two-group ran-
domized controlled trials (often followed by non-experimental post hoc analysis to
answer questions regarding individual components and their interactions). In partic-
ular one important challenge is to whittle down a large list of potential components,
by screening out the least active components. Factorial designs are ideally suited to
this endeavor [9].
The primary goal of this chapter is to consider the use of full and fractional
factorial designs in screening out inactive components so as to aid in the development
of high quality multicomponent interventions. We discuss how many of the criticisms
prevalent in the literature concerning the use of full and fractional factorial designs
no longer hold or are of lesser importance in screening1 trials. A secondary goal is
to provide an operationalization of screening trials using full and fractional factorial
designs.
The present work is motivated by our participation in the design of a web-based
smoking cessation study called Project Quit [88] that utilized fractional factorials.
For illustrative purposes, we present a slightly modified version of Project Quit,
following [62]. The investigators decided to study six components Depth of outcome
expectations, Depth of efficacy expectations, Depth of success stories, Personalization
of message source, Mode of message framing, and Exposure schedule (depth refers to
the degree to which the communication was tailored to the background information
on each individual). Since varying all six components across all possible levels in a
single study was logistically prohibitive, the investigators decided to move forward
1Here the term screening refers to screening of intervention components, not screening of study participants.
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in phases, where results of the research conducted in the first phase would inform
the second, and so on [25, 62]. The goal of the first phase was to identify the active
components and screen out inactive components. Each component was varied at two
levels, as is common in screening studies. In addition all individuals were provided
a 10-week free supply of nicotine patches. The investigators decided to use a 16-cell
fractional factorial design (see section 3.3 for details). The primary outcome was
self-reported seven-day point-prevalence abstinence at the 6-month follow-up from
the date of randomization. More information on this study can be found in [88] and
[62], and also in Chapter II of this dissertation.
The remainder of this chapter is organized as follows. Section 3.2 addresses com-
mon criticisms against the use of full and fractional factorial designs for developing
multicomponent interventions. We provide an operationalization of the screening
trials in section 3.3. Examples of possible follow-up studies are given in section 3.4.
We conclude with an overall discussion in section 3.5. Technical review material on
fractional factorial designs appears in the appendix (at the end of this chapter).
3.2 Factorial Designs for Screening Studies
Factorial designs were originally developed in the context of agricultural experi-
ments [108, 36] and are now used in other areas including engineering [9, 107] and
marketing research [29]. Their use in the medical and behavioral fields has been
limited; however there have been a number of papers discussing the usefulness of
these designs in medication and intervention trials [16, 13, 14, 103, 102, 23].
Prior to discussing common criticisms and concerns, we provide a brief review of
both the design and analysis of screening studies. In screening, two-level factorial
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designs, where all components are studied at two levels (these levels can be either
present vs. absent, or two ethically acceptable doses of the component), are usually
used since the goal is to identify important components rather than identify the op-
timal level of each component. If a two-level factorial design involves k components,
then the total number of treatment combinations studied is 2k. Each of the 2k cells
in the design corresponds to a group of subjects assigned to a particular treatment
combination. In screening experiments, k is often large, rendering a full factorial
design with 2k cells infeasible. In such cases, fractional factorial designs (FFDs) [11]
offer a useful alternative since they use fewer cells (see below for more discussion).
For example, in the Project Quit study, a full factorial design with six components
would need 26 = 64 cells. But by using an FFD, it was possible to restrict the study
to only 16 cells, and still be able to estimate all the main effects and some two-way
interactions under reasonable assumptions.
In case of a continuous outcome, the analysis of a 2k full factorial design (or a
2k−p FFD) with total sample size n can be done using a linear regression model. One
can use a model of the form Y = Xβ + ε, where Y represents the n × 1 vector of
observations on the outcome, X is the n ×m design matrix, β is a m × 1 vector of
unknown parameters (m = 2k for full factorial and m = 2k−p for FFD, with more
parameters if baseline variables are included in the analysis model), and ε is the n×1
vector of errors. It is assumed that E(ε) = 0 and Cov(ε) = σ2I. The design matrix
consists of an intercept column, plus columns corresponding to each component and
their interactions of different order coded in −1/1 (i.e., different factorial effects).
The least squares estimator for β along with its covariance matrix are given by
β̂ = (XTX)−1XTY, Cov(β̂) = σ2(XTX)−1.
Note that the estimates of usual ANOVA quantities of interest like the main effect of a
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component or the interaction between two or more components are directly related to
the least squares regression estimates β̂, provided the design matrix is coded in −1/1.
As discussed by Byar et al. [15], the main effect of a component A1 is estimated by
2β̂A1 , A1A2 interaction is estimated by 4β̂A1A2 , and so on. In general, a p-component
(1 ≤ p ≤ k) interaction, say Ai1 . . . Aip (with 1 ≤ i1, . . . , ip ≤ k), is estimated by
2pβ̂Ai1 ...Aip . If variance heterogeneity across different cells is anticipated in a study,
one can use a robust estimator, e.g. sandwich estimator [104] of the covariance
matrix given by
(XTX)−1XT (diag(Y −Xβ̂))2X(XTX)−1
in the linear regression model. But sample sizes should not be too small for this
estimator to work well. Wu and Hamda [107] provide alternative methods to deal
with variance heterogeneity. As discussed by Montgomery et al. [53], the regression
approach can be used for unbalanced2 data, and can estimate the factorial effects
controlling for baseline or stratification variables. In case of binary (more generally,
categorical) outcomes, the regression approach can be generalized via a generalized
linear model. For example, if the outcome is binary, a logistic regression model can
be used to analyze the data from a factorial design [107, Ch. 13]. See [62] and [88]
for examples of such analyses.
3.2.1 Addressing Criticisms against Factorial Designs
Within the biostatistics literature, factorial designs have been assessed primarily
in the context of medication trials; the objective has been to evaluate the usefulness
of a combined medication over a single medication. In contrast, our objective is to
2Balance means that each level of each component appears in same number of cells and is assigned to the same
number of subjects.
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screen out inactive components of a multicomponent intervention; thus full and frac-
tional factorial designs play a different role from that of evaluation. In this context,
many of the common concerns re cost, feasibility, ethics, toxicity of combination
drugs, interpretation of main effects in presence of active interactions, and concern
about power for detecting interactions become moot or of lesser importance. Indeed
many different complaints against factorial designs stem from a few fundamental
issues and hence can be categorized as follows:
1. There are attractive alternatives to FFD.
2. It is not feasible to simultaneously implement multiple multicomponent inter-
ventions.
3. Some components cannot be crossed due to toxicity or ethical considerations.
4. The interpretation of main effects when interactions exist is complicated.
5. Power is low, or in other words the required sample size is high.
In the following, we address these broad classes of criticisms against factorial designs
in the present context of screening studies for developing multicomponent interven-
tions.
Attractive alternatives to FFD
The traditional approach of empirically developing multicomponent interventions,
sometimes called the treatment package strategy [47, 103, 102], is to formulate a
“likely best” intervention based on existing literature, theory, and clinical experi-
ence. Additionally investigators may use information from limited experimentation
with some of the components either in stand-alone trials or in trials in which one
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component is varied at a time while the remaining components are set at fixed lev-
els. Implicitly one often assumes that more treatment is always better so the “likely
best” intervention includes many components. An additional implicit assumption is
that any ill effects due to including inactive components are minor. The developed
multicomponent intervention is then evaluated in a standard two-arm randomized
trial. These two-arm trials are confirmatory in that they are designed to provide
high quality information on whether the multicomponent intervention performs bet-
ter than the standard; they are not designed to provide direct information on which
components are active, whether they have been set at optimal levels, and whether
there is any interaction between the components [86]. To address the latter ques-
tions, investigators may use observational analyses, such as a dose-response with the
level of subject adherence to the treatment as the dose [68, 1, 96, 97], or theory-
based mediational analysis [103, 106]. The intervention is often refined based on
the findings of these analyses, and then the refined version is tested in another two-
arm randomized trial. Sometimes several such iterations are performed to refine the
multicomponent intervention.
The main problem with this approach is that it depends heavily on the non-
experimental, observational analyses. As is well-known [44, 72, 74], findings that
are not based on randomization are contaminated by the likely presence of unknown
confounders3 (e.g. the variables that affect both the receipt of a component and the
outcome). As a consequence, the effects of individual components and interactions
may be misinterpreted resulting in a suboptimal intervention. Collins et al. [22] pro-
vided a head-to-head comparison between the above approach and an experimental
procedure using FFDs in an extensive simulation study. This comparison was based
3In the literature on FFDs, the term confounding often refers to aliasing of effects. Here we use confounding to
mean mixing of treatment effects with effects of other variables that affect both the receipt of treatment and the
outcome, and thus keep confounding distinct from aliasing.
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on a simulated model involving five components, varying levels of adherence to each
component, an unknown confounder, and a continuous outcome. Also, the model in-
cluded an antagonistic interaction between two components. The simulation results
showed that the FFD-based experimental approach outperformed the traditional ap-
proach (two-arm randomized trial followed by observational analyses) in terms of
various criteria, e.g. optimizing the mean outcome of the final intervention and iden-
tifying the best multicomponent intervention. See chapter IV for further details. Of
course the relative merit of the FFD-based experimental approach depends on the
degree of confounding; using observational analyses to investigate interactions might
work well when the unknown confounder is only weakly related to the receipt of the
components or the outcome.
Another alternative to FFDs is to conduct a series of dismantling or subtractive
trials [103] where a “more complete” version of the multicomponent intervention is
compared with a reduced version with one or more components eliminated. A close
variant of this is known as the constructive strategy [103] or treatment augmentation
design [45], where a base intervention is compared with an augmented version in
which one or more components are added to the base intervention. Yet another al-
ternative is known as the comparative treatment strategy [103], where several versions
of the intervention are directly compared. For example, if there are k components
under consideration, a comparative strategy would compare (k + 1) experimental
arms: k arms, each setting a single component at the high level and the rest at the
low level, plus a control arm where all components are set at the low level. The
above three approaches (i.e., dismantling, constructive, and comparative strategies)
sometimes come under the umbrella term of single-factor designs [23] whenever the
experimental arms under comparison differ by manipulating a single factor.
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Note that there are several problems with using a series of single-factor experi-
mental designs to construct a multicomponent intervention. First, as discussed by
Box et al. [9, pp. 510-513], the use of single-factor designs often tacitly assumes that
the effect of one component is independent of the levels of other components. This
is not true in general, e.g. when there is a sizeable interaction between the compo-
nents. Thus adopting a single-factor design often implicitly assumes that there is
no interaction. Because of this limitation, using a series of single-factor designs to
construct a multicomponent intervention may fail to achieve the best intervention.
The second problem regarding single-factor designs arises in designing the tri-
als, e.g. deciding which factor to add (in constructive strategy) or subtract (in
dismantling strategy), or which two versions of the multicomponent interventions
to compare (in comparative strategy). These decisions are often driven by theory,
cost, burden, or the results of observational analyses. To the extent that the results
are driven by observational dose-response analyses of the amount of treatment re-
ceived, they are vulnerable to confounding bias. As a consequence, in the sequence
of single-factor trials conducted to find the best multicomponent intervention, active
components may be accidentally eliminated in a dismantling strategy, and less ac-
tive components may be erroneously added earlier than more active components in
a constructive strategy.
A third problem with single-factor designs is that they often require many more
subjects than comparable factorial designs to achieve similar power [23], rendering
factorial designs a more efficient choice.
To summarize, in contrast to the treatment package strategy or the single-factor
designs, inference about individual components in FFDs are strictly based on ran-
domization, and hence less vulnerable to confounding bias. Furthermore, single-
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factor experiments are not equipped to take care of interactions, and often have
higher sample size requirement. Although some aliasing of effects happens in FFDs,
the investigator can control this based on prior substantive knowledge (see below for
more discussion on aliasing). Thus by using FFDs, one often trades uncontrolled
confounding for controlled aliasing. Thus full and fractional factorial experimental
designs offer a gold standard for developing multicomponent interventions. In the
following, we will discuss feasibility.
Feasibility of the design
When the number of components (k) is moderately large, full factorial designs may
be impractical due to cost of designing and implementing too many cells, i.e., making
each treatment combination work together and ensuring implementation fidelity by
staff [103]. This criticism has been the main motivation behind the development of
FFDs. It is possible to select an FFD with substantially fewer cells, but still estimate
the main effects (and sometimes important two-way interactions) without bias and
with the same precision as in a full factorial design under plausible assumptions. A
full factorial design allows the estimation of every individual factorial effect, including
all higher order interactions. However, in absence of compelling prior theory or
evidence to the contrary, third- and higher-order interactions are likely negligible
in size in most multicomponent interventions [9, 62]. FFDs sacrifice the ability to
estimate some of these higher order interactions, and in return, enable the study to
have fewer cells. The choice of interactions to be sacrificed is informed by scientific
theory, past studies, and investigator’s experience. The practical price paid to buy
the economy offered by an FFD is that the effects of interest, such as the main
effects and two-way interactions, are aliased with some higher order interactions.
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When two or more effects are aliased, one can estimate only the sum of the aliased
effects. To overcome this problem, ideally an FFD is chosen in which each “aliased
bundle” includes only one effect that is a priori believed to be active, with any other
effects included in the bundle likely negligible in size. If this is not possible, follow-
up experiments [52, 107, 25] can be conducted to settle any ambiguity about which
effects are most important in the aliased bundle of effects. The above ideas were
used by both Project Quit [88] and Guide to Decide [62] to design FFD trials. A
technical review of aliasing and FFDs is given in Appendix A.
The strong use of theory and investigators’ experience in determining which inter-
actions to alias in an FFD is often initially disconcerting to scientists. Note however
that in a two-arm randomized trial of a multicomponent intervention vs. control,
the multicomponent intervention must be determined completely by theory and in-
vestigator’s experience, and furthermore in these two-arm trials every factorial effect
(main effects and interactions) is aliased with every other effect. Thus all analy-
ses concerning individual components hinge on the use of a correct model; if the
model is too simple then finding out what each effect is estimating is often difficult
or even impossible. In this regard, FFDs offer a clearly better option in that the
entire aliasing pattern is under the investigator’s control, and there are principled
ways (e.g. follow-up experiments) to disentangle any aliased effect. Moreover in
non-experimental studies (that often follows the two-group comparisons) in which
often the receipt of treatment depends on adherence to or availability of certain
components, staff decisions as to who to offer what treatment etc., the resulting
confounding is uncontrolled.
Often concerns about feasibility are intertwined with a perceived need to include
many subjects in each cell of the design; this may occur because investigators er-
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roneously think that comparisons between individual cells will be required. This
however is not the case; see below for a discussion of this along with power consid-
erations. None-the-less there are some situations in which investigators are unable
to hire sufficient staff so as to implement multiple multicomponent interventions or
are unable to train the staff to implement multiple multicomponent interventions
simultaneously. In these settings FFDs are not feasible.
Inability to cross some components
To use factorial designs, one must be able to cross the components without chang-
ing dose (i.e., all combinations should be implementable). This has been a fundamen-
tal concern regarding the use of factorial designs in medication trials. In medication
trials, toxicity often precludes the combined use of multiple components (e.g. drugs)
unless the dosage is altered [16, 67]. That is, the combination of drug A and drug B
uses lower doses of both A and B, compared to the case when either drug A or drug
B is used alone. In such cases, the components lose their meanings, and factorial
designs become inappropriate. Here we consider only those components, that when
crossed, retain their meaning. This includes most behavioral, delivery, or imple-
mentation components, as well as multiple medications as long as they use different
biological pathways.
When some components cannot be crossed, the clinical trials literature provides
some approaches. Byar et al. [15] discussed incomplete factorial designs along with
analysis strategies to take care of such cases. These designs are full or fractional
factorial designs, minus some unpermitted combinations. Although these designs
are not balanced (see the second footnote for a definition of balance), one can still
estimate many of the relevant factorial effects.
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Interpretation of main effects
It is well-known that the definition of the main effect, in the presence of sizeable
interactions [16, 67], differs from investigators’ conceptual definition of the effect of
a component. To address this criticism, here we provide precise definitions of main
effects and simple effects that commonly arise in various designs for multicomponent
interventions, and establish their interrelationship.
For simplicity, consider a 2 × 2 factorial design with two components, say A1
and A2, and continuous outcome Y . The presence and absence (or, high and low
level) of each component is coded +1 and −1 respectively. Let µ(−,−), µ(−,+), µ(+,−)
and µ(+,+) be the mean outcomes corresponding to the absent-absent, absent-present,
present-absent, and present-present cells of the design respectively. At the population
level, the main effect of the component A1 is defined by
1
2
(E1 + E2), where E1 =
(µ(+,+) − µ(−,+)) and E2 = (µ(+,−) − µ(−,−)) are two simple effects, denoting the
effect of A1 when A2 is fixed at high and low level respectively. Thus the main
effect of A1 is defined as the average
4 of the two simple effects E1 and E2, and hence
can be interpreted as the effect of A1 when half the subjects in the population are
exposed to (the high level of) A2 and the remaining half are not. On the other hand,
when conceptualizing the treatment effect of A1, an investigator usually thinks of
the simple effect denoting “the effect of A1 in absence of A2” [67, p. 506], i.e., E2.
In absence of interaction between the components, this mismatch does not cause a
problem since the two simple effects are equal. However, the main effect could be
very different from the simple effect of A1 in presence of a sizeable interaction.
4The main effect is usually defined as the average of simple effects as presented above. However, in general, a
weighted average over the distribution of the simple effects in the population may be a better definition.
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If a dismantling strategy is followed (dismantling A1 from the full package involv-
ing both A1 and A2), then the effect estimated is simply (µ(+,+)−µ(−,+)) = E1. This
effect could also be estimated if the constructive strategy is followed (augmenting
A1 to the base intervention consisting of A2 only). Thus these alternative designs
estimate simple effects rather than main effects. Lastly one can imagine a treatment
package effect, e.g. (µ(+,+)−µ(−,−)), which is estimated when the “likely best” pack-
age consisting of the present or high level of all the components is compared with a
control consisting of the absent or low levels of all the components. This does not
correspond to any of the simple effects.
For three two-level components, the main effect of a component A1 is defined as
1
4
(E1 + E2 + E3 + E4), where E1 = (µ+,+,+) − µ(−,+,+)), E2 = (µ(+,+,−) − µ(−,+,−)),
E3 = (µ(+,−,+) − µ(−,−,+)), and E4 = (µ(+,−,−) − µ(−,−,−)) are the four simple effects
(and also can be interpreted as the effects resulting from different dismantling or
constructive trials). The most common simple effect is E4, i.e., “effect of A1 in
absence of other components”, and is often conceptualized as the treatment effect
of A1. In general, for a setting involving k two-level components, there are 2
k−1
simple effects that can be interpreted as effects resulting from different constructive
or dismantling trials. The main effect is simply the average of these 2k−1 simple
effects.
To more clearly understand the alternative definitions and how they differ in
the presence of an interaction, consider a regression formulation. Suppose the true
data-generating model, where A1, A2 are coded in 0/1, is given by
Y = b0 + b1A1 + b2A2 + b12A1A2 + ε.(3.1)
If we use a regression analysis with the −1/1 coding, e.g. we fit β0 + β1A1 + β2A2 +










































(this main effect continues to be the average effect of A1 on Y over the levels
of A2). In contrast, the two simple effects of A1 are b1 (effect of A1 when A2 is
absent), and b1 +b12 (effect of A1 when A2 is present). The main effect and the effect
commonly conceptualized as the treatment effect of A1, i.e., b1, differ by the quantity
1
2
b12 in presence of an active interaction (b12 6= 0). If we apply the reasoning of the
Hierarchical Ordering Principle5 [107] to this setting, then in general we expect that
b12, if nonzero, is likely of smaller size than b1 and b2.
To summarize, when there is an interaction, the main effect has the interpretation
of the average effect of A1 on Y over the levels of other components. This is quite
different from what is often conceptualized as the treatment effect of A1, e.g. the
simple effect of A1 on Y setting other components to lower level. However the crucial
point is that in screening studies, the goal is to screen components efficiently, and
not to estimate either the simple effect or the main effect of a component per se. The
important issue for screening is whether this difference in definition impinges on our
ability to screen components. So in this context, the concern about the definition of
main effects is actually a concern about power to screen components. We address
this concern below in great detail (see the third issue below under the Power heading).
5The Hierarchical Ordering Principle is an assumption commonly made in design of experiments in the absence
of substantive theory or prior results suggesting otherwise. It states that lower-order effects are more likely to be
important than higher-order effects, and effects of the same order are equally likely to be important.
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Power
Several issues lead to concerns about power when factorial designs are considered.
First, investigators sometimes use factorial designs to evaluate or compare a few mul-
ticomponent interventions, e.g. compare one cell against another cell [42], or other-
wise assess simple effects. This naturally leads to a large sample size requirement
since each cell (group of subjects) must be large. However to screen components,
we primarily focus on main effects and sometimes also a few anticipated two-way
interactions. The focus on main effects and lower order interactions for the purpose
of screening can be partially justified by the Hierarchical Ordering Principle [107],
which says that main effects and lower order interactions are likely more important
than higher order interactions. Recall the main effect of a factor is an average of all
the 2k−1 simple effects. Thus even though several components are studied, the total
sample size required for assessing the significance of a main effect is the same as that
for a two-group trial involving a single component (for example in a linear model, the
estimator of the main effect is proportional to the difference between the means of
two groups of cells; all cells in the FFD belong to one or the other group). Further-
more, in the multiphase approach to intervention development [25, 62], ascertaining
the best treatment combination is done through follow-up studies, in which one usu-
ally focuses on only a few combinations of components while holding the levels of the
remaining components constant. See section 3.4 for a discussion of follow-up studies.
Second, there is concern about the loss of balance and subsequent loss of power
due to study dropout. In most intervention studies, patient dropout is inevitable,
thus resulting in unequal cell sizes. As discussed by Montgomery et al. [53], this is
an issue for all clinical trials rather than a criticism of factorial designs; modern-
day missing data techniques will be needed in the analysis, as is the case with any
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randomized clinical trial.
A third issue related to power is how one should formulate the test statistics to
detect the effects of treatment components in a screening study. Note that in a
screening study the goal is to screen out inactive components, and not to estimate
either a simple effect or a main effect per se. Below we show that even when the data
are generated using non-zero simple effects, often the power to detect the resulting
main effect is higher than the power to detect the original simple effect. Hence in
a screening study, formulating the test statistics based on main effects is in general
better than formulating test statistics based on simple effects. To discuss this con-
sider again the 2×2 factorial design with two components, say A1 and A2, r subjects
per cell, and the continuous outcome Y . The true data-generating model is specified
in terms of simple effects, which is consistent with an investigator’s conceptualiza-
tion. Thus the true data-generating model is given by (3.1) in which the components
A1, A2 are coded in 0/1. In the following, we show that by basing the test statistic
on main effects, we can in general screen non-zero simple effects with greater power.
For simplicity, assume Var(ε) = σ2 is known (and homogeneous across cells). If
a linear regression model with 0/1 coding is used as in Piantadosi [67, pp. 508-509]
then the following model is fit:
β0 + β1A1 + β2A2 + β12A1A2.(3.2)
Here β1, the coefficient of A1, is a simple effect representing the comparison of the
(1, 0) cell with the (0, 0) cell, i.e., β1 = µ(1,0)−µ(0,0) = b1, where µ(1,0) is the population
mean of Y in the (1, 0) cell, and so on. Now β1 is estimated by β̂1 = Ȳ(1,0) − Ȳ(0,0),
where Ȳ(1,0) is the sample mean of Y in the (1, 0) cell, and so on. Clearly, E(β̂1) = b1,
42
and










So the signal-to-noise ratio (SNR) governing the power to screen A1 when basing the

























× (the average of 2 simple effects),
and is estimated by the sample version β̂1 (where µ is replaced by Ȳ ). Then,
























So the signal-to-noise ratio governing the power to screen A1 when basing the test












A measure of relative efficiency of the two ways of forming the test statistics in
















In absence of an interaction (i.e., b12 = 0), η =
√
2 > 1, and hence basing the test
statistic on main effects gives higher power for screening components. In case of
synergistic interaction (i.e., b1 and b12 are of same sign), η is even larger, leading
to higher power. Even in case of antagonistic interaction (i.e., b1 and b12 are of
opposite sign), the way of basing the test statistic on main effects gives higher power
in screening components (i.e., η > 1) if b1 < 0 and 0 < b12 < −(2 +
√
2)b1, or if
b1 > 0 and 0 > b12 > −(2 −
√
2)b1. If we have k (≥ 2) components in a factorial
experiment, and there may be a two-way but no higher-order interaction in the true
data-generating model, then the relative efficiency of the two ways of forming the
test statistic (measured by η) increases with k. A verification of this appears in
Appendix B.
To illustrate the power implications of basing the test statistics on main effects
rather than simple effects in a regression analysis, we consider a small simulation
study with the data-generating model Y |A1, A2 ∼ N(µ = b0 + b1A1 + b2A2 +
b12A1A2, σ = 1), where A1, A2 are coded in 0/1. That is, the data-generating model
is specified in terms of simple effects (as is usually conceptualized by an investiga-
tor). The coefficients b1, b2 are set according to Cohen’s [21] small or medium effect
size (i.e., b1 = b2 = 0.2, 0.5). The coefficient b12 of the interaction term is varied:
b12 = b1, b1/2, 0,−b1/2,−b1 (i.e., same size and sign as b1, half the size of and same
sign as b1, absent, half the size of b1 but of opposite sign, same size as b1 but of
opposite sign). A 0.05 level of significance is used throughout, while varying the
sample size: n = 100, 200, 500. The goal of this simulation is to illustrate that even
when the data-generating model is specified in terms of simple effects, basing the
test statistics on main effects leads to higher power in most settings than basing
the test statistics on simple effects. Note that the signal-to-noise ratios govern the
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corresponding powers. In the following, we consider the power to screen A1 both in
presence and absence of an interaction term A1A2 (synergistic as well as antagonis-
tic). Table 3.1 contains a Monte Carlo estimate (using 1000 iterations) of the power
for screening A1 under different scenarios.
Table 3.1: Power to screen A1 in absence and presence of an interaction
n Interaction Interaction b1 = 0.2 b1 = 0.5
Size (b12) Type Using Using Using Using
simple effect main effect simple effect main effect
Same (= b1) synergistic 0.1030 0.2910 0.4150 0.9550
Half (= b12 ) synergistic 0.1030 0.2290 0.4150 0.8730
100 Absent (= 0) none 0.1030 0.1720 0.4150 0.6830
Half (= − b12 ) antagonistic 0.1030 0.1110 0.4150 0.4420
Same (= −b1) antagonistic 0.1030 0.0820 0.4150 0.2290
Same (= b1) synergistic 0.1690 0.5440 0.6920 1.0000
Half (= b12 ) synergistic 0.1690 0.3940 0.6920 0.9870
200 Absent (= 0) none 0.1690 0.2840 0.6920 0.9430
Half (= − b12 ) antagonistic 0.1690 0.1720 0.6920 0.7510
Same (= −b1) antagonistic 0.1690 0.1040 0.6920 0.3940
Same (= b1) synergistic 0.3460 0.9210 0.9740 1.0000
Half (= b12 ) synergistic 0.3460 0.8040 0.9740 1.0000
500 Absent (= 0) none 0.3460 0.6050 0.9740 1.0000
Half (= − b12 ) antagonistic 0.3460 0.3730 0.9740 0.9870
Same (= −b1) antagonistic 0.3460 0.1890 0.9740 0.8040
Note that in Table 3.1, the power to screen A1 is higher in general when the test
statistic is based on main effects compared to when it is based on simple effects (e.g.
comparing the 4th vs. 5th column, and comparing the 6th vs. 7th column), except
when the interaction is of same size and opposite in sign as the simple effect of A1 (as
expected from the above discussion). However according to the Hierarchical Ordering
Principle [107], interactions are usually of smaller order of magnitude than the main
effects (absent strong scientific theory to the contrary), and hence this is a fairly
unlikely scenario. A secondary point to note is that when the test statistic is based
on main effects, there is a decrease in power to screen A1 as the interaction term b12
decreases from highly synergistic to highly antagonistic (moving down the 5th and
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7th columns). However, when the test statistic is based on simple effects, the power
for screening A1 is independent of the size of the interaction term b12 (moving down
the 4th and 6th columns). But the decrease in power in the 5th and 7th columns due
to interaction often does not pose a serious threat (as compared to the loss of power
from using simple effects in the test statistic) if the goal is to screen components,
since in most settings the way of basing the test statistic on main effects gives better
power anyway.
A fourth issue related to power is the power to detect interactions. Factorial de-
signs are often criticized on the ground that the power to detect an interaction is
much lower than the power to detect a main effect of the same size [67, 53]. However,
it is also recognized that factorial designs are the only experimental designs that can
systematically investigate interactions. To overcome the low power for detecting in-
teractions in a confirmatory (not screening) trial, the general recommendation in the
literature [16] is that if an interaction is strongly anticipated based on the investiga-
tor’s prior knowledge, the study should be powered with larger sample size. When
criticizing factorial designs on the ground of low power for interactions in the present
context of screening trials for developing multicomponent interventions, it is useful
to consider the pros and cons of the possible alternatives. The natural alternative
is to conduct non-experimental analyses using treatment adherence or other post-
randomization outcomes as doses or factor levels from a randomized trial or to use
observational data sets. As discussed previously, the relative merit of FFDs over the
above strategy depends on the degree of confounding in the data. The crux is that
the low power to detect interactions in a factorial design can be offset by its ability to
perform valid estimation and inference, and its ability to control (by design) aliasing
in a principled manner, in comparison to observational analyses.
46
3.3 Operationalization of Screening Trials
This section provides an example of how screening trials can be operationalized
using FFDs. The choice of an appropriate FFD is often governed by prior knowledge
regarding the intervention to be developed. To move forward, two definitions are
useful. An FFD is completely characterized by its defining relation [107], a rule from
which the aliasing pattern of the FFD can be obtained. Moreover, FFDs are some-
times categorized by their resolution. Loosely speaking, the higher the resolution,
the better is the design. Resolution IV and resolution V designs are considered here.
In particular, in a resolution V design, main effects are aliased with 4-way (or higher
order) interactions, and 2-way interactions are aliased with 3-way (or higher order)
interactions. Likewise in a resolution IV design, main effects are aliased with 3-way
(or higher order) interactions, and 2-way interactions are aliased with other 2-ways
(or higher order). Typically resolution V designs are better than resolution IV de-
signs, but resolution V designs require more cells. Hence investigators may adopt
lower resolution designs due to cost and feasibility constraints. Further review of the
defining relation and resolution are given in the Appendix A. In the following, we
first discuss the screening design used in the Project Quit study. Next, we discuss a
general approach to construct screening designs (e.g., appropriate FFDs).
Screening design in the Project Quit study
Denote the six components of the Project Quit study, e.g. depth of outcome
expectations, depth of efficacy expectations, depth of success stories, personalization
of message source, mode of message framing, and exposure schedule by A1, A2,
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A3, A4, A5, and A6 respectively. In this study, prior knowledge suggested that
the interactions between outcome expectations and efficacy expectations (A1A2),
outcome expectations and success stories (A1A3), outcome expectations and message
framing (A1A5), and efficacy expectations and message framing (A2A5) were likely
active (let us call them anticipated interactions), and that all other interactions
should be negligibly small in size. So a design was constructed such that one could
estimate the A1A2, A1A3, A1A5, and A2A5 interactions, assuming all others to be
small. Due to cost constraints, 16 cells were used in the design. So the design used
was a 16-cell FFD with the defining relation
(3.3) I = A1A2A4A5 = A1A3A4A6 = A2A3A5A6.
This is a resolution IV design where some of the 2-way interactions are aliased with
other 2-way interactions. The anticipated 2-way interactions are listed on the left-





Note that the anticipated interactions were aliased with other 2-way interactions that
were considered negligible, and hence were estimable without bias. The defining rela-
tion I = A1A2A3A5 = A1A3A4A6 = A2A4A5A6 was “cleverly” chosen to accomplish
this goal. Of course, the investigator’s assumption about the interactions could be
wrong. But one can verify any critical working assumptions made in the screening
study using follow-up studies [25].
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Screening design construction in general
As a starting point we assume that regardless of the number of components stud-
ied, the number of cells used can be at most 16 (equal to the number of cells used in
the Project Quit study). Of course this number can vary from one setting to another.
If 4 or fewer components are to be studied, a full factorial design can be used. If 5
components, say A1, . . . , A5 are to be studied, then one should use the resolution V
FFD with the defining relation I = A1A2A3A4A5 (this is the case in the Guide to
Decide project described by [62]). If 6 components, say A1, . . . , A6 are to be studied,
resolution IV designs are generally recommended. If prior knowledge suggests a few
anticipated 2-way interactions, an FFD can be chosen carefully so that the antic-
ipated 2-way interactions are not aliased with each other (this consideration often
drives the construction of the design). Assuming the unanticipated interactions to
be negligible, this ensures that each anticipated interaction can be estimated without
bias. When there is only one anticipated interaction, any 16-cell resolution IV FFD
can be used. However, for two or more anticipated interactions, choices are limited.
Software (e.g., SAS PROC FACTEX, JMP, Minitab) can be used to generate the
designs in such cases (they provide one possible design that satisfies the constraints
of resolution and/or anticipated interactions, instead of giving the complete list of
possible designs). For two or three anticipated interactions, the complete set of rec-
ommended designs are given in Table 3.2.
Power and sample size in screening trials
In a screening trial using a factorial design, the power calculation used to size
the trial focuses on main effects of each component. Thus the power calculation
is similar to that of a two-arm randomized trial in that the two levels of a single
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component (averaged over the levels of all other components) serve as the two arms.
Below we provide the power calculation for the Project Quit study as an example.
For Project Quit, the planned initial recruitment size was 2000; this number was
chosen to achieve a total sample size of 1500 for the analysis, anticipating a 75%
response rate at the 6-month follow-up. Assuming no differential attrition across
cells, this meant roughly 750 subjects per level of each intervention component. The
primary outcome was binary, e.g. seven-day point-prevalence smoking cessation at
the 6-month follow-up. So the power analysis involved binomial calculations (using
a normal approximation) assuming a baseline average cessation rate of 10% found
in a previous study [33]. For each main effect, the sample size of 750 per level
provides approximately 80% power for detecting a 4.5% difference in cessation rates.
The same power characteristics exist for each of the six components. Note that to
Table 3.2: Recommended resolution IV FFDs under varying anticipated interactions
Case Anticipated interactions Recommended designs
of the form (defining relations)
1 A1A2, A3A4 I = A1A2A3A5 = A1A3A4A6 = A2A4A5A6
(no component shared) I = A1A2A3A5 = A2A3A4A6 = A1A4A5A6
I = A1A2A4A5 = A1A3A4A6 = A2A3A5A6
I = A1A2A4A5 = A2A3A4A6 = A1A3A5A6
I = A1A2A3A6 = A1A3A4A5 = A2A4A5A6
I = A1A2A3A6 = A2A3A4A5 = A1A4A5A6
I = A1A2A4A6 = A1A3A4A5 = A2A3A5A6
I = A1A2A4A6 = A2A3A4A5 = A1A3A5A6
2 A1A2, A1A3 I = A1A2A4A5 = A1A3A4A6 = A2A3A5A6
(one component shared) I = A1A2A4A6 = A1A3A4A5 = A2A3A5A6
I = A1A2A4A5 = A1A3A5A6 = A2A3A4A6
I = A1A2A5A6 = A1A3A4A5 = A2A3A4A6
I = A1A2A4A6 = A1A3A5A6 = A2A3A4A5
I = A1A2A5A6 = A1A3A4A6 = A2A3A4A5
3 A1A2, A3A4, A5A6 same as case 1
4 A1A2, A1A3, A4A5 I = A1A2A5A6 = A1A3A4A6 = A2A3A4A5
I = A1A2A4A6 = A1A3A5A6 = A2A3A4A5
5 A1A2, A1A3, A2A4 I = A1A2A5A6 = A1A3A4A5 = A2A3A4A6
I = A1A2A5A6 = A1A3A4A6 = A2A3A4A5
6 A1A2, A1A3, A1A4 I = A1A2A5A6 = A1A3A4A5 = A2A3A4A6
7 A1A2, A1A3, A2A3 same as case 2
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achieve the same power to detect the same difference in cessation rates, one would
need the same sample size in a usual two-arm study (so the sample size requirement
is not increased by using a factorial design). The formula for calculating power in








p(1− p) + (p + ∆)(1− p−∆)
)
,
where n is the total sample size, p is the baseline cessation rate, ∆ is the change in




point of a standard normal distribution, and Φ is the standard normal distribution
function.
Additional practical considerations regarding study duration and cost
A primary advantage of using factorial designs in a screening study lies in its
efficiency, i.e., its ability to answer several screening questions (regarding multiple
intervention components) quickly from a single study. The use of an FFD-based
approach in Project Quit was motivated by the concern that advances in communi-
cation technologies were moving well beyond the understanding of message content,
presentation, and delivery principles in the field of smoking cessation. Investigators
of this study realized that research using the field’s most widely-used designs (e.g.
randomized trials with a small number of groups) [33, 87, 89, 91] would take years
to assess even a few basic questions. By the time these findings would be dissemi-
nated, the technology and target populations would likely have been changed (e.g.
become more sophisticated in their understanding of a communications channel),
and consequently the field would continue to lag behind. Thus in the context of this
concern, the FFD-based multiphase approach provided a huge benefit by offering a
shorter total study duration to answer so many questions compared to the alternative
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designs.
There are two kinds of cost associated with designing multicomponent interven-
tion trials, e.g., (1) cost associated with sample size requirement, and (2) cost of
designing and implementing different cells. We have already discussed that the sam-
ple size requirement does not go up by using an FFD. The only additional cost of
designing an FFD over a two-group trial is the cost of designing and delivering too
many versions of the intervention which might limit the applicability of FFDs in cer-
tain settings. In case of Project Quit, the intervention was delivered entirely through
the internet. So the delivery of 16 versions of the multicomponent intervention did
not cost additional staff time and training over and above the cost of software pro-
gramming to generate the different versions, which turned out to be manageable.
See Collins et al. [23] for a detailed comparison of FFDs with single-factor designs
(dismantling, constructive and comparative trials) from a resource management per-
spective.
Screening analysis
The screening analysis uses a linear model (in case of continuous outcome) or a
generalized linear model (in case of binary or categorical outcome). A few consider-
ations to be made during the analysis are:
1. The level of significance α for testing the effects in the screening study might
be set higher than 0.05 to achieve greater power for detecting effects. α can
be viewed as a tuning parameter of the procedure. One possible choice is to
use α = 0.1 for the main effects and anticipated two-way interactions, and a
Bonferroni-corrected 0.1 level for the unanticipated interactions.
2. As an alternative (or augmentation) to performing significance tests at the
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screening study, one can rank-order the absolute values of the test statistic
corresponding to the factorial effects (or equivalently p-values) and move to
follow-up studies with the largest m. Then this m becomes a tuning parameter
of the procedure. This approach should work better in case all individual effects
are small, but together they produce some effect (significance test often accepts
the null hypothesis of no effect in such cases, and hence perform poorly). To be
resistant to the noise in the data, one may choose to rank-order only the main
effects and anticipated interactions. This strategy with m = 3 was followed in
the simulation study described in [22].
Examples of the screening analysis in the Guide to Decide and Project Quit studies
can be found in [62] and [88]. Based on the screening analysis of the Project Quit
study, the investigators decided to move to the follow-up study with the components
having the highest two p-values (e.g. success stories and message source). Fur-
thermore since three of the components (outcome expectations, efficacy expectations
and success stories) were set at levels corresponding to high depth of tailoring versus
low depth of tailoring, the investigators considered a regression of overall depth of
tailoring (over all components) and found that as the depth of tailoring increased
the smoking cessation rate increased. Hence the investigators decided to use a high
depth of tailoring in the follow-up study.
3.4 Follow-up Studies
In the process of developing a multicomponent intervention, an investigator often
conducts follow-up studies involving the significant6 factorial effects from the screen-
6Throughout this section, we use the term significant loosely to mean any effects that come out important
according to the screening analysis strategy outlined above.
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ing study to fine-tune the results, e.g. finding the best level (or dose) of a significant
component which is either continuous or has more than two levels by a dose-response
experiment (where the subjects are randomized to ethically acceptable doses of the
component), or de-aliasing significant aliased interactions by a smaller factorial ex-
periment. In this section, first we provide a few hypothetical examples (of varying
level of complexity) of follow-up studies to provide some general intuition, and then
briefly describe the follow-up phase of the Project Quit study.
Hypothetical examples
In the following examples, for simplicity, we assume that there are 6 components
in the study, e.g. A1, . . . , A6, out of which only A1 is a 3-level component (say, high,
medium, low levels – only high and low levels are studied at the screening trial) and
the rest are binary (high and low). High values of the outcome are preferred. A
16-cell resolution IV FFD is used as the screening design (see section 3.3 for details).
We assume throughout that three-way (or higher-order) interactions are negligible
in size compared to the noise in the data; hence even though main effects are aliased
with three-way interactions, we assign the estimated effect to the main effect.
Example 1: Suppose the significant effects along with their signs based on screening
analysis are:
A1(+), A2(+), A3(−), A5(−), A2A3 = A4A5(−),
where the aliased interaction A2A3 is unanticipated but A4A5 is anticipated. So the
investigator may dismiss A2A3 as a possible effect and assign the observed effect
entirely to A4A5. Since the main effect of A4 is insignificant, the main effect of A5 is
negative, and the A4A5 interaction is negative, it is reasonable to set A4 at its high
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level and A5 at its low level to maximize the mean outcome. Also, from the signs
of the estimated main effects of A2 and A3 (and ignoring the unanticipated A2A3
interaction), A2 and A3 should be set at their high and low levels respectively. Since
A6 is insignificant, it should be set at low level. Hence the follow-up study might
be a 2-group trial varying A1 at its medium and high levels (since its main effect
is positive), setting A2, A3, A4, A5, and A6 at high, low, high, low, and low level
respectively. If A4 is an expensive or particularly component then it may be worth-
while to affirm that A4 is not significant yet its interaction with A5 is. In that case,
the follow-up study can be a 8-group trial where the two levels of A1 (high/medium)
are crossed with two levels of A4 and A5 each. In all the groups, A2, A3, and A6
should be set at high, low, and low level respectively.
Example 2: Suppose the significant effects along with their signs based on screening
analysis are:
A1(+), A3(+), A1A3 = A2A6(−),
where aliased interaction A1A3 is anticipated but A2A6 is unanticipated. As before,
we dismiss A2A6 based on prior considerations and assign the observed effect to
A1A3. The follow-up study could be a 6-group trial crossing three levels of A1 with
two levels of A3. In all the groups, the levels of A2, A4, A5, and A6 should be set at
the low level.
Example 3: Suppose the significant effects along with their signs based on screening
analysis are:
A1(+), A2(+), A3(+), A5(−), A2A3 = A4A5(−),
where both the interactions A2A3 and A4A5 involved in the aliased bundle are unan-
55
ticipated. Since the main effect of A4 is insignificant, the main effect of A5 is negative,
and the aliased A4A5 interaction is negative (even though we are not sure if the ob-
served effect is really due to A4A5), one reasonable step would be to set A4 at its high
level (provided the high level of A4 is not very expensive or burdensome) and A5 at
its low level (note that our decision about the optimum levels of A4 and A5 would
be same when A4A5 effect is really negative as when A4A5 is null). Also, we would
set A6 to the low level. If there is concern about the potential A2A3 interaction then
the follow-up study could be a 8-group trial, where medium and high levels of A1
are crossed with the two levels of A2 and A3 each to form the 8 groups (setting A4,
A5, and A6 at high, low, and low levels respectively).
Follow-up study design of Project Quit
An alternative to the follow-up studies outlined above is provided by Project Quit
study, in which all components were two-level (hence a dose-response experiment
was unnecessary) and no (unanticipated) aliased interaction were found significant
(hence no de-aliasing experiment was necessary). The investigators decided to study
different aspects (not studied in the screening trial) of the two important components
(e.g. success stories and message source). The decision was to vary message source
at two levels (high/low) of additional personalization, and to vary success stories
in terms of the archetype (language and picture) of the hypothetical character in
the story at three levels (e.g. a rebel, care-giver, or self-made character). Two new
two-level components, e.g. order (of appearance on the web site: success stories
first vs. health advice first) and email quit status request (yes/no) were added to the
follow-up study. Subjects randomized to the “yes” level of email quit status request
were contacted by the study staff at regular intervals about their quit status. The
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follow-up study consisted of 25 groups in total: 24 groups from the 2 × 3 × 2 × 2
factorial structure of the above 4 components, plus a control group. In all groups, the
original components from the screening trial not studied in the follow-up study were
set as follows: deeply-tailored efficacy expectation and outcome expectation mes-
sages, gain framing, and multiple exposures. All three levels of the success stories
were also deeply-tailored. The control group received the best intervention accord-
ing to the results of screening study (e.g., highly personalized source at the first
session only, deeply-tailored story with fixed archetype as in the screening study,
deeply-tailored efficacy expectation and outcome expectation messages, gain fram-
ing, and multiple exposures) – they did not receive any email about their quit status.
3.5 Discussion
Multicomponent interventions are becoming increasingly common in health sci-
ences. In this chapter, we have addressed the criticisms and misconceptions regarding
the use of full and fractional factorial designs (e.g. attractive alternatives to and fea-
sibility of such designs, inability to cross components, interpretation of main effects,
and concerns about power) in the context of screening studies to develop multicom-
ponent interventions. Other issues regarding the use of factorial designs, as discussed
by Couper et al. [26], are slower recruitment rate (since subjects need to meet the in-
clusion criteria for all the components) and potential lower compliance (due to a more
complicated treatment protocol) than single-component trials. However, these are
common to any studies of multicomponent interventions, and not problems specific
to factorial designs.
We provided some examples of follow-up studies that often need to be conducted
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(e.g. to de-alias significant aliased interactions) after the completion of the screening
study. Further strategies for conducting follow-up studies can be found, for example,
in [52] and [107]. Also, in case there is at least one component with more than
two levels (e.g. a continuous component), dose-response experiments [10, 61] where
subjects are randomized to ethical doses should be used to find the optimal dose of
these components. Operationalizing a wider variety of follow-up studies needs more
targeted future research.
In our discussion of FFDs, we assumed that third- and higher-order interactions
are negligible [9, 62]. This is not a binding constraint. Suppose prior knowledge
suggests that interactions up to order 3 involving a certain component are likely
important, whereas even two-way interactions involving some other components are
negligible. One can still use a carefully chosen FFD [107].
One setting in which factorial designs are not well suited is when the main effects
of all the individual components are weak, but there are some high-order interac-
tions in the data-generating model that produce a strong effect on the outcome (i.e.,
a setting where the Hierarchical Ordering Principle is violated). Another important
caveat regarding the use of factorial designs for developing multicomponent inter-
ventions is the presence of nested components (e.g. levels of component B are nested
within the levels of component A). Generalization of the usual factorial designs called
nested factorials [85, 3] can incorporate nested components. Analysis of such designs
can employ mixed-effects models [82]. A somewhat similar issue is when some inter-
vention components are applied most naturally in a grouped setting. For example,
some intervention components are provided to all patients at a clinic [30] or to all
children in a classroom or school [37]. Development of an experimental framework
tailored to such settings is an avenue for future research. To conclude, FFDs provide
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a powerful tool for conducting screening studies to aid in the development of multi-
component interventions.
3.6 Appendix A: Defining Relation and Resolution of an FFD
The defining relation of an FFD specifies the aliasing. Suppose a study involving
five components, say A1, . . . , A5, is restricted to 16 cells (as in the Guide to Decide
study described in [62]). Then a 1
2
fraction of the 25 full factorial design should
be used. With 16 cells, one can construct a full factorial with 4 components, say
with A1, . . . , A4. The strategy is to alias the fifth component, say A5, with the 4-
way interaction A1A2A3A4. This means, the column (in the design matrix) of A5 is
identical to that of the element-wise product of the columns of A1, A2, A3, and A4,
i.e., A5 = A1A2A3A4. Note that all the elements in any of the columns are either
+1 or −1. So element-wise product of any column with itself leads to the identity
column, say I (with all its entries +1). In particular, A5A5 = I. Multiplying both
sides of the equation A5 = A1A2A3A4 by A5 gives
I = A1A2A3A4A5.(3.4)
The condition (3.4) completely specifies the aliasing pattern of the 25−1 FFD under
consideration, and hence called its defining relation. The alias of any factorial effect
can be found by multiplying both sides of (3.4) by that effect and then using the
facts that AjI = Aj and AjAj = I for all j. The word A1A2A3A4A5 is called the
defining word. The length (i.e., number of elements) of the defining word is called
the resolution of the design. So the design specified by (3.4) is a resolution V design.
In a resolution V design, the main effects are aliased with 4-way interactions, and the
2-way interactions are aliased with 3-way interactions. In a setting where the third-
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or higher-order interactions are negligible, resolution V FFDs are almost as good
as the full factorials in that the main effects and 2-way interactions are estimable
without bias.
However due to cost and feasibility constraints, one often has to use smaller (than
1
2
) fraction of full factorial designs, leading to lower resolution. The Project Quit
study described before used a resolution IV FFD. In the following, we illustrate reso-
lution IV designs with an example. Suppose there are 6 components, say A1, . . . , A6
in a study that is restricted to 16 cells (as in Project Quit). This means constructing
a 1
4
fraction of the 26 (= 64 cells) full factorial design. With 16 cells, one can con-
struct a full factorial with 4 components, say with A1, . . . , A4. Now, the strategy is
to make the columns of the remaining two components A5 and A6 identical to some
higher-order interactions. One such choice is to set A5 = A1A3A4 and A6 = A2A3A4.
Using the same rules as before, one gets I = A1A3A4A5 from the first aliasing rela-
tion, and I = A2A3A4A6 from the second aliasing relation. Multiplying these two, a
third equation I = A1A2A5A6 follows. Thus the defining relation of this FFD is
(3.5) I = A1A3A4A5 = A2A3A4A6 = A1A2A5A6.
By definition, (3.5) is a resolution IV design, since the length of each defining word is
4. In a resolution IV design, the main effects are aliased with 3-way or higher-order
interactions, but the 2-way interactions are aliased with other 2-ways.
3.7 Appendix B: Relative Efficiency of The Two Ways of Forming The
Test Statistic
Here we show that if there are k (≥ 2) components in a factorial experiment, and
there may be a two-way but no higher-order interaction in the true data-generating
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model, then the relative efficiency of the two ways of forming the test statistic (mea-
sured by η) increases with k.
Note that in 0/1 coding, regardless of the total number of components (k), β1,
the coefficient of A1, is a simple effect given by µ(1,0,...,0)−µ(0,...,0); the corresponding
estimator is β̂1 = Ȳ(1,0,...,0) − Ȳ(0,...,0), where Ȳ(1,0,...,0) is the sample mean of Y in the
(1, 0, . . . , 0) cell, and so on. It follows that E(β̂1) = b1, and V ar(β̂1) = 2σ
2/r (since
β̂1 is a comparison of two cells each of size r). So when using simple effects to form
the test statistic, the signal-to-noise ratio governing the power to detect A1 in the 2
k














× (the main effect of A1) = 1
2
× (the average of 2k−1 simple effects),
which is estimated by its sample version β̂1 where all the µ’s in the expression of
simple effects are replaced by the corresponding Ȳ ’s. In case there is a two-way
interaction (b12) but no higher-order interaction in the true data-generating model,
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CHAPTER IV
Comparison of the MOST Approach and a Single
Randomized Trial for Developing Multicomponent
Interventions
This chapter provides a head-to-head comparison between two competing ap-
proaches to developing multicomponent interventions: (a) the classical approach
consisting of a standard two-group randomized trial followed by post hoc analyses,
and (b) the MOST approach. Here we present results from a simulation study in
which the classical and the MOST approaches were applied to the same randomly
generated data. As we will see, the MOST approach resulted in better mean inter-
vention outcomes under medium or large effect size, whereas the classical approach
resulted in better mean intervention outcomes when the effect size was small.
4.1 Introduction
In this chapter, we describe a simulation study to contrast and explicate the rela-
tive advantages and disadvantages of two different approaches to empirically building
and evaluating multicomponent interventions. The more typically used approach, la-
beled here the classical approach (sometimes called the treatment package strategy),
consists of constructing a likely best intervention a priori, evaluating the interven-
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tion in a standard randomized controlled trial, and following it up with observational
analyses. On the other hand, the emergent MOST approach [25, 62] discussed in
Chapter I involves programmatic phases of empirical research and discovery aimed
at identifying individual component effects and the best combination of components
and levels. The MOST approach makes use of fractional factorial designs (FFD)
discussed in Chapter III.
This chapter describes a simulation study that addresses the following questions:
(1) Which approach, the classical or the MOST, is better at identifying (a) more
efficacious interventions? (b) the correct set of intervention components and levels?
(c) the best setting of a component with several possible settings? (d) the active
components that should be included? (e) the inactive components that should be
excluded? (2) What is the impact of overall intervention effect size on the absolute
and relative performance of the two approaches? We also briefly summarize the re-
sults of additional simulations performed to assess the generalizability of the results.
4.2 Methods
4.2.1 Overview of the Simulation
In this simulation the behavioral scientist intends to build and evaluate a multi-
component intervention. Based on existing literature, prior study results and clinical
experience, the scientist has identified five intervention components, denoted A1−A5,
each of which is hypothesized to have a positive effect on an outcome variable Y .
Components A2−A5 can be either included in the intervention or not included, thus
they can assume only two levels. A1 can assume three levels: low, medium, or high.
In building and evaluating the behavioral intervention the scientist has access to
N = 1200 subjects. We chose N = 1200 because it is not uncommon for behavioral
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intervention trials to have sample sizes at least this large; examples include [88],
which had N = 1848 subjects; [89], which had N = 3971 subjects; and [77], which
had N = 1421 subjects. In appendix C, we summarize the results of additional
simulations using smaller and larger sample sizes.
Data sets were generated using a procedure (described below) designed to reflect
some of the complexity that can occur in real intervention studies. Both the classical
approach and the MOST approach were separately applied to each generated data
set. The goal of each approach was to arrive at the most efficacious intervention,
expressed in terms of an outcome variable Y . The classical approach consisted of
selecting components and dosages a priori and performing a two-group randomized
trial using all available subjects. This was followed by post-hoc analyses. By con-
trast, the MOST approach began with an initial screening experiment for preliminary
selection of components, based on a portion of the sample. This was followed by a
set of refining experiments to finalize selection of components and dosages, based on
the remaining portion of the sample.
4.2.2 Data Generation Model
The data generation model used in this simulation study was inspired by the
conceptual model used in a large behavioral intervention trial called Fast Track [27].
This data generation model was designed to be only partially consistent with the
behavioral scientist’s hypotheses described above, in order to mimic the commonly
occurring real-life situation in which some of an investigator’s hypotheses are true
and some are false. Although the investigator hypothesized that all five components
would have a positive effect on the outcome, in the data generation model the only
active components were A1, A2, and A4. In addition, the relation between A1 and Y
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Figure 4.1: Data generation model for simulation.
was curvilinear such that the medium level of A1 was associated with higher values
of Y than other levels of A1 (and the high level of A1 was associated with higher
values of Y than the low level of A1). Thus the optimal configuration of intervention
components is A1 included in the intervention and set to the medium level; A2 and
A4 included; and A3 and A5 not included.
Additional complexity was introduced in the data generation model in three dif-
ferent ways to reflect circumstances that frequently occur in real-world intervention
settings. First, to represent the amount of each component actually received by
(rather than assigned to) participants, adherence variables Ad1 −Ad5 were modeled
for each of the five components A1−A5. Adherence was modeled as 100% for A2 (i.e.,
Ad2 = A2) and partial for the remaining components (0 ≤ Ad ≤ A); see Appendix
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A for details. Second, to mimic the confounding that can result when post-hoc anal-
yses use non-randomized comparisons, unknown participant characteristics that can
affect both adherence and the outcome were included. In a real-life setting, there
are likely to be many such confounding variables. For simplicity, they were modeled
here by a single unobserved binary variable called Type, with Type = 1 representing
participants likely to register a higher value of Y , and Type = 0 representing partici-
pants likely to register a lower value of Y . In addition to its relation with Y , Type is
positively associated with the level of adherence (except Ad2 which is always 100%)
so that participants are more likely to adhere and hence receive more treatment if
Type = 1. Thus, Type causes a spurious positive correlation between the levels of
adherence (except Ad2) and Y , which in turn makes the estimates of component ef-
fects based on the post-hoc analyses positively biased. Third, when participants are
offered multiple behavioral intervention components of varying attractiveness, some
may adhere closely to the more attractive components and reduce their adherence
to the others. This has a deleterious effect if some of the less attractive components
are more efficacious. To mimic this, a negative interaction was modeled between A4
and A5, such that A5 induced a reduced adherence to A4. This means that all else
being equal, an intervention that included both A4 and A5 is less efficacious than
one that included A4 without A5. This phenomenon is called subadditivity.
Figure 1 is a pictorial representation of the data generation model, details of which
are provided in Appendix A. Figure 1 is a directed acyclic graph [66]; the presence of
an arrow from one variable to another indicates that the former variable may have
a causal effect on the latter variable. A square represents an observed variable, and
a circle represents an unknown, and hence unobserved, variable. The absence of an
arrow indicates conditional independence; for example, given the variable Ad1, Y
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is independent of A1. In Figure 1 all relations have a positive (if any) dependency
except the A5 to Ad4 relation, which is labeled with a minus sign. To maintain
simplicity and clarity of exposition no other population heterogeneity was built into
the simulation. Thus in the following analyses it would not be useful to control
for observed participant characteristics or other observed pretreatment variables.
Averaging over the distribution of Type and Ad1−Ad5 produces the marginal linear
model
(4.1) E[Y |A1, . . . , A5] = c0 + c1A1 + c11A21 + c2A2 + c4A4 + c45A4A5
Furthermore the variance of Y given A1, . . . , A5 is a function of the components
A1, . . . , A5, that is, the variance is nonconstant (see Appendix A).
4.2.3 Experimental conditions
In the simulation there were three effect size conditions for the interventions, cor-
responding to Cohen’s [21] benchmark values for standardized effect sizes of small
(d = 0.2), medium (d = 0.5) and large (d = 0.8). Effect sizes were defined in terms
of the ideal intervention as a whole, in other words, for the two-group comparison
of the best treatment combination (A1 set to medium, A2 and A4 included, A3 and
A5 not included) versus a control group. Active main effects were roughly equal in
magnitude, and the effect corresponding to the active interaction (A4A5) was roughly
half the size of the main effects. All other intervention component main effects and
interactions were set to 0. Across all three effect size conditions, the effect of Type
was set equal to d = 0.9. For each of the three effect size conditions, 1000 simu-
lated data sets of N = 1200 random experimental subjects were generated. Each
generated data set was used twice: once for the classical approach, and once for the
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MOST approach. All the results presented in Tables 4.1-4.3 are averages based on
the 1000 simulated data sets.
4.2.4 Operationalization of the classical and the MOST approaches
This section contains a brief overview of the operationalizations of the classical
and the MOST approaches. A detailed description of the MOST approach can be
found in Appendix B.
The classical approach
The classical approach employed all N = 1200 experimental subjects in a single
randomized trial of the multicomponent treatment vs. control, followed by post hoc
analysis. The treatment group was given an intervention consisting of A1 set to
“high” and all of the other components included; the control group was given an in-
tervention with A1 set to “low” and none of the other components included. Because
only homogeneous subpopulations were considered in this simulation study (see the
data generation model above), there were no pretreatment variables to be controlled.
As is traditional, a two-group comparison was performed for the overall efficacy of
the intervention. However, regardless of the outcome of this comparison, decisions
about whether individual components should be retained in the intervention were
based on post-hoc dose-response analyses (with the levels of adherence Ad1, . . . , Ad5
as doses) on the treatment group of subjects as follows:
Step 1: Identify components with sufficient variation in dose to enable dose-
response analyses. Received dose (adherence) could vary between 0 and 2 for A1 and
between 0 and 1 for A3 − A5 (adherence was always 100 percent for A2, so there
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was no variation). Any components for which naturally occurring variation in dose
was greater than an arbitrary threshold of 0.01 were considered to have sufficient
variation to enable dose-response analyses. Any components with variation in dose
less than 0.01 could not be examined further, and were automatically included in
the final intervention.
Step 2: Multiple regression. The outcome Y was regressed on the following vari-
ables: doses of all components with sufficient variation in dose; two-way interactions
between them; and, if Ad1 was included in the regression, a quadratic term for Ad1
(an implicit assumption here is that the scientist knows that A1 has more than two
levels).
Step 3: Select components and levels. The estimated regression function was eval-
uated at each combination of levels of the components that had sufficient variation
in dose (by plugging in possible values of A’s in place of Ad’s, e.g., 0, 1, or 2 for
Ad1, and 0 or 1 for Ad3 − Ad5). The level combination that produced the largest
predicted value of Y was identified.
Step 4: Final intervention. The final intervention identified by the classical ap-
proach consisted of (a) the low-variation components identified in Step 1, each set to
1 (2 in the case of A1), plus (b) the configuration of components and levels identified
in Step 3.
The MOST approach
The MOST approach used the same N = 1200 subjects as the classical approach,
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but employed N = 800 subjects in an initial screening phase and reserved N = 400
for a subsequent refining phase. In the screening phase, a factorial experiment in-
volving all five components was conducted, with only the low and the high levels
of A1 included. To conserve resources, a 16-condition balanced fractional factorial
design was used instead of a 32-condition complete factorial; see Appendix B for a
technical discussion about the particular choice of fraction and the rationale behind
it. This experiment was used to identify significant main effects and 2-way interac-
tions. Intervention components were selected based on the results of the screening
phase using the following decision rules. First, any component with a significant
main effect and not involved in a significant interaction was selected for inclusion in
the intervention. A main effect was deemed significant if it possessed one of the three
largest positive t-statistics or if the associated t-test was significant at the 0.10 level
and positive. The decision rule to take the three largest was arbitrary to an extent;
below we summarize the results of additional simulations that varied this decision
rule. Interactions were deemed significant if the associated t-test was significant at
the 0.10 level. Next, any components involved in significant two-component interac-
tions were examined further. The combination of the two components that produced
the highest marginal cell mean on Y was selected for inclusion. This procedure is
described in more detail in Appendix B.
In this study the purpose of the refining phase was to determine the optimal value
of A1. Therefore, if A1 and all its interactions were insignificant, the refining phase
was not conducted. Otherwise, additional experimentation to revise the selected
level for A1 was conducted as follows: (a) If the main effect of A1 was significant
but no interactions were significant, the refining experiment was a two-group com-
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parison of level 2 of A1 against level 1 of A1. In this experiment the remaining
components were set at the levels indicated by the screening phase. The results of
this experiment yielded the best level for A1. (b) If there were one or two significant
interactions involving A1, a factorial experiment was conducted crossing A1 with the
components involved in the interactions, with the remaining components set to the
levels indicated by the screening phase. These results yielded the best levels for A1
and for the components that interacted with A1. More detail appears in Appendix B.
Evaluation of outcomes of each approach
Because in this simulation the true data generation model is known, it is possible
to use this model to evaluate the performance of the classical and the MOST ap-
proaches. After the final intervention was determined using either the classical or the
MOST approach, the data generation model was used to compute the expectation of
the distribution of Y that would be obtained if the intervention were applied to all
subjects in the population. These expectations, E(Y )classical and E(Y )MOST , were
the outcome variables used to evaluate the performance of each approach. In real
life this step would instead consist of conducting a large confirmatory randomized
trial comparing the final intervention to an appropriate control group. This is called
the confirming phase of the MOST approach [25, 62].
4.3 Results
As was described above, the classical approach and the MOST approach each
identifies a final multicomponent intervention for every simulated data set. The
two final multicomponent interventions are then evaluated using the known data
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generation model. All the results presented in Tables 4.1-4.3 are averaged over the
1000 simulated data sets.
Table 4.1: Mean Intervention Outcome under Classical and MOST Approaches (averaged over 1000
simulated data sets)
Effect Size E(Y )classical E(Y )MOST Difference Maximum
(standard error) (standard error) (standard error) Possible E(Y )
Small 1.72 (0.00) 1.69 (0.01) 0.03 (0.01) 1.99
Medium 2.35 (0.01) 2.58 (0.01) -0.23 (0.02) 2.99
Large 3.01 (0.02) 3.75 (0.01) -0.74 (0.02) 4.00
Table 4.1 shows the mean outcome of the classical and MOST approaches, the
mean difference between them, and standard errors. For reference, the maximum
possible mean outcome value is included. Table 4.1 shows that in the small effect
size condition E(Y )classical was approximately two percent larger than E(Y )MOST ,
indicating that in this condition the average intervention outcome was slightly better
for the classical approach. In the medium and large effect size conditions the average
intervention outcome was about 10 and 25 percent larger, respectively, for the MOST
approach. The difference between the classical and MOST approaches is significant
at the 0.05 level in every condition.
Table 4.2: Comparison of Classical and MOST Approaches on E(Y) (Percentage of Data Sets)
Effect Size E(Y )classical E(Y )MOST Neither
Higher Higher Higher (tied)
Small 54.2 40.8 5.0
Medium 32.3 62.4 5.3
Large 14.9 75.7 9.4
Table 4.2 shows the percent of data sets in which each approach “won” by identi-
fying an intervention that yielded a larger value of the outcome E(Y ). In the small
effect size condition the classical approach was about 1.3 times more likely than
the MOST approach to identify an intervention that yielded a larger E(Y ). In the
medium and large effect size conditions the effect was reversed, with the MOST ap-
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proach about 1.9 and 5.1 times more likely, respectively, to identify an intervention
that yielded a larger E(Y ).
Table 4.3: Accuracy of Component Selection under Classical and MOST Approaches (Percentage
of Data Sets)
Effect Size Classical MOST












Table 4.3 depicts the accuracy with which each approach selected intervention
components and levels for inclusion in the intervention or identified components for
exclusion. The first section of the table shows the percent of data sets in which
the correct configuration of components and levels was identified. As expected, this
number increased for both approaches as effect size increased. In every condition the
MOST approach was much more likely to identify the correct configuration. One
reason for the better performance of the MOST approach is that it identified the
medium level of A1 as optimal more frequently than the classical approach (in 61.3
vs. 11.8 percent of data sets in the small effect size condition, 90.7 vs. 31.0 percent
in the medium effect size condition, and 98.3 vs. 40.6 percent in the large effect size
condition). Another reason is that the MOST approach included the component A5
(which, as described above, produced a subadditive effect in presence of the active
component A4) in the intervention much less frequently (in 25.4 vs. 57.6 percent of
data sets in the small effect size condition, 11.5 vs. 57.2 percent in the medium effect
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size condition, and 6.5 vs. 56.9 percent in the large effect size condition).
The second section of Table 4.3 shows the percentage of data sets in which all ac-
tive components were correctly selected, irrespective of whether inactive components
were mistakenly selected, and irrespective of the selected level of A1. The classi-
cal approach outperformed the MOST approach on this criterion for the small and
medium effect size conditions. For the MOST approach the performance improved
dramatically (from 14.5 to 73.5 percent) as the effect size increased. However, the
performance of the classical approach was fairly constant (ranging from 48.2 to 48.5
percent) across the effect size conditions.
The third section of Table 4.3 shows the percentage of data sets in which all inac-
tive components were correctly excluded, irrespective of whether some active inter-
vention components were incorrectly excluded. Across all three effect size conditions
the performance of the MOST approach was better than the classical approach. Here
too performance improved as effect size increased for the MOST approach, but not
for the classical approach.
Other sample sizes and numbers of main effects retained
We conducted some additional simulations in order to investigate whether the
results reported here held across variation along two dimensions. One was sample
size. The other was the decision rule used in the MOST approach for selecting in-
tervention components for inclusion based on main effects estimates. In a series of
nine simulations we investigated three different sample sizes, N = 600, N = 1200,
and N = 2500; and three different decision rules: retention of the intervention com-
ponents corresponding to the largest two, three, and four main effects. The overall
pattern of results was very consistent. In general the classical approach tended to
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produce a larger E(Y ) than the MOST approach in conditions involving both a small
effect size and a small sample size. The MOST approach tended to produce a larger
E(Y ) than the classical approach in the medium and large effect size conditions, even
in the small sample size condition. The MOST approach tended to produce larger
E(Y ) than the classical approach when the decision rule called for retaining a larger
number of main effects; in the conditions in which the four largest main effects were
retained the MOST approach consistently produced the larger E(Y ), even in the
conditions involving both a small effect size and a small sample size. More details
can be found in Appendix C.
4.4 Discussion
The simulation reported here compared one possible operationalization of the
MOST approach to one possible operationalization of the classical approach. Which
approach performed best depended upon which criterion was used to evaluate the
approaches and also upon intervention effect size.
When the two approaches were evaluated in terms of overall intervention outcome,
the classical approach performed better than the MOST approach when the inter-
vention effect size was small, and the MOST approach performed better than the
classical approach when the intervention effect size was medium or large. The MOST
approach suffered somewhat from a lack of power in the small effect size condition.
One reason why the classical approach tended to be outperformed by the MOST ap-
proach in the medium and large effect size conditions is confounding by the unknown
participant characteristic Type. Type introduced a positive bias that had an impact
on the results of the classical approach primarily in two areas. First, this positive
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bias made the high level of A1 look better than the medium level in the post-hoc
dose-response analysis. Second, the positive bias also masked the subadditive effect
of A5 on A4 in the post-hoc analysis, sometimes leading to the incorrect inclusion
of the component A5. Type had little or no impact on the results of the MOST
approach because this approach depended primarily on estimates of main effects and
interactions based on data from randomized experiments, which are much less likely
to be biased by confounding than are post hoc non-experimental analyses [83].
When success at identifying the best combination of components and levels was
the criterion, the MOST approach was the better of the two across all effect sizes.
This is directly due to the greater impact of confounding on the classical approach
as compared to the MOST approach. For example, confounding by Type made the
classical approach more likely to lead to choose an incorrect level of A1, as men-
tioned above, even though a quadratic term was appropriately included in regression
analyses.
When the two approaches were evaluated in terms of successfully including all
of the active components, the classical approach performed better than the MOST
approach in the small and medium effect size conditions, and the MOST approach
performed better when effect sizes were large. The MOST approach detected active
components at a higher rate as effect size increased, due to the corresponding in-
crease in power. By contrast, the classical approach detected active components at
a relatively constant rate across increasing effect sizes. The primary reason for this
is that in our operationalization of the classical approach the components with low
variability in adherence were automatically included, irrespective of effect size. For
example, the active component A2 was always included because the received dose,
Ad2, was always equal to the assigned value of A2 (100% adherence).
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The MOST approach outperformed the classical approach in all effect size condi-
tions when the criterion was successfully identifying inactive or potentially counter-
productive components that should be eliminated from the intervention. Again, this
is attributable to the differential impact of confounding. Because Type is positively
associated with both Y and Ad’s, it induced a positive bias in the non-experimental
analyses that led the classical approach to a preference for including components
over excluding them.
Choosing an approach to intervention building
Our results suggest that when medium or large intervention effect sizes are an-
ticipated, the use of the MOST approach is likely to result in identifying a more
potent intervention than the classical approach. When a small intervention effect is
anticipated, the choice is less clear. Multicomponent interventions with small overall
effect sizes may be made up of either (a) mostly inactive components with one or two
components with relatively large effect sizes, or (b) fairly equally efficacious but weak
components, which together produce a detectable aggregate effect even though no
individual component has a detectable effect. In situation (a), the MOST approach
may be helpful in identifying the inactive components. In situation (b), in order
to perform well the MOST approach would need to be powered to detect the weak
individual component effects. Here the classical approach may be a better choice.
One drawback of the classical approach is that all subjects in the treatment arm
receive all the components, and so the main effects of all the components and their
interactions of every order are confounded (aliased). In contrast, in the MOST
approach if a fractional factorial design is used, the main effects and two-way in-
teractions are confounded with only higher order interactions deemed negligible in
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size, and hence do not affect the results. If a full factorial design is used there is no
confounding of main effects and interactions.
It is possible that some other variant of the classical method, e.g., dismantling
experiments [103], would have performed better than the approach used in the simu-
lation reported here. However, as long as post hoc analyses on non-randomized data
(e.g., adherence) are used, the performance of any version of the classical method will
depend on the degree of confounding present in the data. In situations in which the
degree of confounding is very low or nonexistent, the version of the classical approach
we have used and other reasonable variants would probably perform as well as the
MOST approach. Of course, in most cases the degree and nature of confounding is
not under the investigator’s control and may be difficult to anticipate. Because the
MOST approach is entirely based on randomization, it is much less vulnerable to
confounding.
Although the MOST approach was better overall at identifying the best configu-
ration of components and levels, the success rate ranged from a high of 52 percent
to a low of about 7.5 percent. Thus there is plenty of room for improvement, partic-
ularly when effect sizes are small. It is possible that an augmented approach or even
an entirely different approach could result in a higher success rate. One promising
avenue for intervention refinement may lie in exploring ideas from engineering pro-
cess control, as discussed in [69].
Differences in resource requirements
One question that arises in considering the MOST approach is whether the ad-
ditional experimentation required by this approach necessarily demands an increase
in cost over the classical approach. The MOST approach calls for a design that can
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isolate the effects of individual components. In the screening phase this will usually
be some variation of a factorial design, requiring implementation of numerous condi-
tions, each of which represents a different version of the intervention. For example, a
full factorial design involving k two-level components requires implementation of 2k
treatment conditions, which may be costly. By contrast, irrespective of the number
of components studied the classical approach typically requires implementation of
only two conditions, a treatment and a control.
Two important costs are experimental subjects and implementation of experi-
mental conditions. In this simulation the MOST approach used exactly the same
number of experimental subjects as the classical approach, suggesting that it is no
more demanding with respect to sample size. When a factorial design is used, given
a fixed number of subjects an investigator may test as many components as desired
– the power to detect every main effect in this way is about the same as testing that
component in a single-component two-group study with the same sample size. This
means that factorial experiments make very efficient use of experimental subjects.
Power and sample size considerations (e.g., for testing main effects) in a factorial
setting can be found in [16, 42, 53, 17]; see also Chapter III.
However, even when in the MOST approach the same number of subjects is used
as in a comparable classical approach, there may be additional costs associated with
implementing a wider variety of versions of the intervention and conducting follow-
up experiments. It may also take more time to implement the MOST approach, and
may require more training of intervention delivery staff. Although these logistics and
costs associated with the MOST approach are a serious consideration, highly efficient
fractional factorial designs offer a way to keep the number of experimental conditions
manageable. Some assumptions about higher-order interactions being negligible are
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necessary in order to take advantage of the economy offered by a fractional factorial
over a full factorial design. The particular fractional design used in the simulations
reported here did not allow estimation of 3-way or higher order interactions; instead,
it required the assumption that they are negligible in size. Many fractional factorial
designs are available. If prior knowledge suggests that some 3-way interactions can
be important, an investigator can choose a different fractional design that allows
estimation of 3-way interactions [107].
Even with a highly efficient design, the investigators in empirical settings some-
times have to make decisions based on results of past studies and auxiliary analysis
performed on data from the current study. This is particularly true when numerous
interactions are anticipated. An example of such an analysis can be found in [88].
The short-term costs of building and evaluating an intervention must be weighed
against long-range costs and benefits. Our results suggest that the MOST approach
may help identify more efficient and streamlined interventions by identifying inactive
components for elimination. As Allore et al. [1, p. 14] noted, “Since each component
of an intervention adds to the overall cost and complexity, being able to directly es-
timate component effects could greatly enhance efficiency by reducing the number of
components introduced into clinical practice”. Our results also suggest that under
many circumstances the MOST approach may be likely to identify a more efficacious
intervention than the classical approach. Thus, in some applications the long-range
gains in terms of increased efficiency and public health benefits expected to result




This simulation was designed to take an initial look at the question of whether the
MOST approach is a reasonable way to build interventions. It involved only a very
small set of conditions out of the infinite number of possibilities that can occur in
practice. There are a number of potentially important factors that were not varied in
the simulation. A few of these are: the underlying structural model, which could be
varied to include features such as more 2-way interactions, higher-order interactions,
and the presence of mediating variables; the degree of confounding, here reflected
by the variable Type; the number of components under consideration; the number
of active vs. inactive components; other effect sizes besides the three used here; the
impact of measurement noise on the outcome variable; the effect of complex data
structures such as nesting (e.g. individuals within classrooms; patients within clin-
ics); incorporating cost and burden in decisions about which components and levels
should make up an intervention; and the operationalization of the classical approach
used. Many other additional factors could be considered. Despite the limitations of
this study and the need for additional research, we believe that the results of the
simulation show clearly that the MOST approach is a promising alternative.
4.4.2 Conclusions
The classical approach is currently the most well-established approach to empiri-
cal development of behavioral interventions. However, an emergent strategy, labeled
here the MOST approach, provides a systematic way of making evidence-based deci-
sions about which components and which levels of the components should comprise
an intervention. Comparison of the two approaches in real-world empirical settings
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is impractical. In the present chapter a simulation was presented that provides this
comparison by modeling a plausible empirical scenario. The results suggested that
the MOST approach merits serious consideration, because it has the potential to
help intervention scientists to build more potent behavioral interventions. Possible
exceptions to this are interventions with a small overall effect size, particularly those
that are the cumulative effect of many weak components. More research is needed
on methods to identify the optimal intervention, and thereby increase public health
benefits.
4.5 Appendix A: Data Generating Model
The data generating model is described below in terms of equations involving the
intervention components (A1 −A5), the measures of adherence (Ad1 −Ad5), an un-
known confounder Type (T ), and the outcome (Y ). In this model, A2−A5 can take
two values: 0 or 1 (absent or present); while A1 can be 0, 1, or 2 (low, medium, or
high). Note that subjects may receive a different dose of a component than that as-
signed. Measures of adherence (Ad’s) simply represent these doses. A multiplicative
model is used below to describe the relation between A’s and Ad’s. The confounder
Type follows a Bernoulli (1/2) distribution.
A → Ad:
Ad1 = (η10 + η11 T + e1) · A1
Ad2 = A2
Ad3 = (η30 + η31 T + e3) · A3
Ad4 = (η40 + η41 T + η42A5 + e4) · A4
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Ad5 = (η50 + η51 T + e5) · A5
where each of e1, e3, e4, and e5 follows a normal distribution N(0, σ
2
e), σe = 0.1.
Note that there is no non-adherence to component A2. The right hand side of
the equations in the above display are truncated such that Adj ∈ [0, Aj],∀j. The
subsequent equations are only approximate due to this truncation.
Ad → Y :
Y = β1 T + β2 Ad1 + β3 Ad
2
1 + β4 Ad2 + β5 Ad4 + εY ; εY ∼ N(0, 3).
Marginal Form of Y , averaged over Ad’s:
Averaging over Ad’s, we get
Y = β1 T + β2 (η10 + η11 T ) A1 + β3
(
(η10 + η11 T )
2 + e21
)
A21 + β4 A2
+ β5 (η40 + η41 T ) A4 + β5 η42 A4 A5
+
(
εY + e1 β2 A1 + 2e1 β3 (η10 + η11 T ) A
2
1 + e4 β5 A4
)
(4.2)
Let eT denote the sum of the 4 terms in the last row of the above display. Note
that the term eT has zero mean but heteroscedastic variance because some of the
ej’s occur in products with the components. Because of zero mean, eT functions like
an error term. The generated Y will have a mean of the form
E[Y |A1, . . . , A5] = 1
2
β1 + β2 (η10 +
1
2










+ β4 A2 + β5 (η40 +
1
2
η41) A4 + β5 η42 A4 A5
= c0 + c1 A1 + c11 A
2
1 + c2 A2 + c4 A4 + c45 A4 A5(4.3)
where each cj is a function of (η, β, σe). In the simulations, we set these parameter
values to ensure certain effect sizes as defined in the following section. Equation (4.3)
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above corresponds to equation (4.1) appearing in the main text.
Standardized Effect Size
In our simulations, we set the parameter values so that the standardized effect
size (Cohen’s d) for the two-group comparison of the best treatment combination
(A1 = A2 = A4 = 1, A3 = A5 = 0) vs. the control where A1 is set to its low level and
all other components are absent (i.e., Ai = 0,∀i) enjoys Cohen’s benchmark values




















Y |Ai = 0,∀i
)]
=
c1 + c11 + c2 + c4
f(η, β, σe)
,(4.4)
where f is some function of η, β, σe as can be seen from (4.2). The numerator follows
from (4.3).
Parameter Values for Specific Standardized Effect Sizes
From now on we denote the parameter values used in a given simulation with a
superscript 0. The true parameter values η0 and β0 are chosen so that the following
conditions are satisfied:
1. The standardized effect size d as defined above attains Cohen’s benchmark val-
ues (small=0.2, medium=0.5, large=0.8).
2. The active main effects (considered in the screening phase) are roughly equal in
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magnitude, while the active interaction is half the size of active main effects:
2c1 + 4c11 = c2 = c4 = c, say(4.5)
c45 = − c
2
3. The middle level of A1 (i.e., A1 = 1) is best, and the main effect of A1 between
levels 1 and 2 (as considered in refining phase) is also equal to the main effects
considered in screening phase, i.e.,
(c1 + c11)− (2c1 + 4c11) = −c1 − 3c11 = c(4.6)
4. The level of confounding, as quantified by β1η11 (= β1η31 = β1η41 = β1η51), is
made equal to c corresponding to the large effect size (d = 0.8).














51 = 0.25; η
0
42 = −0.3125.
If we keep the η’s and σe fixed, then f(η, β, σe) appearing in the denominator of
(4.4) can be written as g(c), a function of just c. Also, each β can be expressed as a





For all three values of d (=0.2, 0.5, 0.8), we solve (4.7) for c by recursive method
(calculating g(c) by Monte Carlo integration). We get c = 0.165, 0.415, 0.667 for
small, medium, and large effect size respectively. From the values of c, we can easily
obtain the β values.
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The β values corresponding to small standardized effect sizes are:
β01 = 2.6680; β
0
2 = 0.9240; β
0
3 = −0.5945; β04 = 0.1650; β05 = 0.2640.
The β values corresponding to medium standardized effect sizes are:
β01 = 2.6680; β
0
2 = 2.3240; β
0
3 = −1.4953; β04 = 0.4150; β05 = 0.6640.
The β values corresponding to large standardized effect sizes are:
β01 = 2.6680; β
0
2 = 3.7352; β
0
3 = −2.4033; β04 = 0.6670; β05 = 1.0672.
4.6 Appendix B: Operationalization of the MOST Approach
As in the classical approach, each scientist following the MOST approach studies
all the five components. In the screening phase only the two extreme levels (out of
three) of A1 are considered. We restrict the number of cells to 16 in our simulations,
so a 16-cell resolution V balanced fractional factorial design with defining word I =
A1A2A3A4A5 is used (see Appendix A of the Chapter III for a technical discussion
on defining word and resolution). The defining word completely specifies the aliasing
pattern in the design. The above choice of design was used in a behavioral study
on breast cancer prevention [62]. Since this is a resolution V design, the 2-way
interactions are not aliased with each other (aliased with three-way interactions,
as can be seen from the defining word). In general, the investigators choose the
defining word based on prior substantive knowledge concerning the potential strength
of higher order interactions relative to the likely noise in the data (e.g. if the size
of any three-way interaction is likely small compared to the noise level of the data,
one can be more confident that the detected two-interaction effect is due to the two-
way interaction and not to a three-way interaction). This is in accordance with the
Hierarchical Ordering Principle [107, p. 112] which states that, absent strong prior
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knowledge, higher order interactions can be expected to be of smaller size than lower
order interactions. Note that in the setting described in the main text (N = 1200
subjects), only 800 subjects are used by each scientist in the screening phase of the
study.
Screening Phase Analysis
The experiment is simulated using the 16-cell balanced fractional factorial design.
A standard analysis of variance (ANOVA) is performed on the outcome Y and the
five components. In the screening phase, the following steps are followed:
1. A 10% level of significance is used for testing the main effects and two-way
interactions (to have greater power).
2. If the no. of significant effects is less than 3, rank-order the absolute values
of the t-statistics corresponding to the main effects only (assuming that main
effects are more likely to be significant than two-way interactions) and identify
the largest 3. Move to the refining phase with the corresponding effects (treating
them as significant).
In step 2 above, we chose the number of components to retain (say, k) to be equal to
3 to ensure that at least 50% of the components always pass the screening phase (3
is the smallest integer greater than or equal to 5/2, 5 is the total no. of components).
Since in general we expect that only a few components are likely to be active, the
choice to carry forward the top 3 components to the refining phase is a reasonable
one. By doing so, we are being conservative about the hypothesized effect of the
components. This is a tuning parameter of the procedure and can vary from one
investigator to another. We have conducted simulations for two other choices of this
number (e.g., k = 2 and 4). A summary of simulation results across all three choices
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of k (e.g., 2, 3, and 4) can be found in Appendix C.
Moving Towards Refining Phase
As mentioned in the main text, a part of the original sample in each simulated
data set is reserved for the refining phase. The refining phase may or may not be
conducted depending on the results obtained in the screening phase. In general the
refining phase is employed in the simulation if (1) the three-level component A1 is
significant in the screening phase, or (2) there is at least one significant interaction
involving A1 (see Algorithm 1 below). The MOST approach, just like the classical
approach, assumes the prior knowledge that A1 is a special component having more
than two levels. The refining phase uses multi-group experiments; standard analysis
of variance, with 5% level of significance is used. In the setting described in the
paper (N = 1200 subjects), the remaining 400 subjects are used by each scientist in
the refining phase of the study.
Algorithm 1
This algorithm is used in the simulation to determine which components should be
retained and which should be rejected, based on the results of the screening phase.
Input: set of components, significant effects (both main and interaction effects),
estimated effect sizes, and signs of effects.
Output: best (treatment) combination.
Initialize: best combination = [0, 0, 0, 0, 0], a 5-component vector. In the following,
we will use the notation best combination(i) to denote the i-th element of the vector
best combination.
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1. Go through the set of components (i = 1 : 5): If main effect and all interactions
of component i are insignificant, set best combination(i) = 0. If main effect of
component i is significant, but none of its interactions are, look at the sign. If
sign(i) = +1, set best combination(i) = 1. Else, best combination(i) = 0.
2. Now for any significant interaction, find [P1, P2] = parent components of that
interaction.
(a) If the main effect of the component P1 (P2) is insignificant, initialize sign(P1) =
0 (sign(P2) = 0). If P1 (P2) is significant, initialize sign(P1) (sign(P2)) to
the sign of its main effect (either +1 or −1), respectively.
(b) Define sign vector as the vector consisting of sign(P1), sign(P2), and sign(interaction).
(c) If sign(P1) = 0 but sign(P2) 6= 0, set sign(P1) = sign(P2)×sign (interaction).
Do a similar operation for P2.
(d) If both parents are insignificant, i.e., sign(P1) = sign(P2) = 0, go to step 4.
3. If sign(P1)×sign(P2) = sign(interaction), set best combination(P1) = (sign(P1)+
1)/2, and best combination(P2) = (sign(P2) + 1)/2.
4. For a significant interaction:
– if sign vector= [0, 0, 1], compare the cell means where both P1 and P2 are
set to +1 (so the interaction P1P2 is also set to +1) vs. where both P1 and
P2 are set to −1 (so P1P2 is set to +1).
– if sign vector= [0, 0,−1], compare the cell means where P1 = +1, P2 = −1
(so P1P2 = −1) vs. where P1 = −1, P2 = +1 (so P1P2 = −1).
– otherwise, do cell-mean comparison of the following four cells: P1 = +1, P2 =
+1 (so P1P2 = +1), P1 = −1, P2 = −1 (so P1P2 = +1), P1 = −1, P2 = +1
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(so P1P2 = −1), P1 = +1, P2 = −1 (so P1P2 = −1).
The combination of (P1, P2) that gives the highest cell mean is used to determine
the best combination. This step implicitly assumes that the four cells do not
differ with respect to other active components.
Note that the order in which step 2 considers interactions impacts the results.
For example if sign(P1) = 0, sign(P2) = −1, sign(P1P2) = −1, sign(P3) = +1,
sign(P1P3) = −1, then the best combination setting for P1 will depend on the order
in which the interactions are considered. The simulations used the natural ordering,
e.g., significant interactions from the ordered list 12, ..., 15, 23, ..., 25, 34, 35, 45
(using the notation ij to denote the interaction AiAj).
Refining Phase
1. When A1 and all its interactions are insignificant, there is no refining phase.
The best treatment combination is found by Algorithm 1.
2. When A1 is significant, but none of its interactions are so, the refining phase
uses a two-group follow-up experiment, in which A1 is varied across the two
groups, setting other components at their optimum level (obtained by applying
Algorithm 1 on the screening phase results). One group receives the intermedi-
ate level of A1 (not studied in screening phase), the other receives one extreme
level depending on the sign of the screening phase estimate of the effect of A1
(the level is the higher extreme if the sign is a +, lower extreme otherwise).
Thus, the best treatment combination is found.
3. If only one interaction involving A1 is significant, a 6-group follow-up experiment
(3 levels of A1 × 2 levels of the other component forming the interaction), setting
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all other components at their optimum levels as found by Algorithm 1, is used.
4. If two interactions involving A1 are significant, then a 12-group (3 × 22 = 12)
follow-up experiment is used in the refining phase.
5. For three or more significant interactions involving A1, conducting follow-up
experiment becomes increasingly problematic (constructing many treatment
groups), and also results become less reliable (low power for comparing many
groups). In our simulations, no refining experiment is conducted in such cases
– the best combination is determined by applying Algorithm 1 to the results of
screening phase. As mentioned in the previous page, the order in which step
2 of Algorithm 1 considers interactions impacts the results. The simulations
used the natural ordering, e.g., significant interactions from the ordered list 12,
..., 15, 23, ..., 25, 34, 35, 45 (using the notation ij to denote the interaction
AiAj). However, these cases occurred very rarely in our simulation, and hence
this step was rarely employed. In real life, investigators can come up with rules
to proceed based on additional analysis (see [88], for an example).
The abstract discussion of Algorithm 1 and refining phase possibilities are made
more concrete below with the help of three simulated examples:
Example 1
Suppose at the screening phase, the significant effects along with their signs are:
A1(+), A2(+), A3(−)
Before running any follow-up experiment, Algorithm 1 will operate on this as follows:
• Best combination is initialized as [0, 0, 0, 0, 0].
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• By Step 1, A1, A2, A3, A4 and A5 are set to 1, 1, 0, 0, and 0 respectively. So
Best combination becomes [1, 1, 0, 0, 0].
Since only the main effect of A1 (but none of its interactions) is significant at the
screening phase, a 2-group follow-up experiment is conducted at the refining phase,
where the 2 groups correspond to the levels 1 and 2 of A1. In both groups, A2, A3,
A4, and A5 are fixed at levels 1, 0, 0, and 0 respectively – as determined by Algorithm
1 above.
Example 2
Suppose at the screening phase, the significant effects along with their signs are:
A1(+), A2(+), A4(+), A1A2(+), A4A5(−)
Before running any follow-up experiment, Algorithm 1 will operate on this as follows:
• Best combination is initialized as [0, 0, 0, 0, 0].
• By Step 1, A3 is set to 0. Best combination remains same as before.
• By Step 2 (a – c), sign vector for the interaction A1A2 is (1, 1, 1), and the sign
vector for the interaction A4A5 is (1,−1,−1).
• By Step 3, best combination becomes [1, 1, 0, 1, 0].
Since one interaction involving A1 is significant at the screening phase, a 6-group
follow-up experiment is conducted at the refining phase, where the 6 groups cor-
respond to the combinations (0, 0), (0, 1), (1, 0), (1, 1), (2, 0), and (2, 1) of the
components A1 and A2. In all 6 groups, A3, A4, and A5 are fixed at levels 0, 1, and
0 respectively – as determined by Algorithm 1 above.
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Example 3
Suppose at the screening phase, the significant effects along with their signs are:
A1(+), A2(+), A5(+), A2A3(−), A3A5(+)
Before running any follow-up experiment, Algorithm 1 will operate on this as follows:
• Best combination is initialized as [0, 0, 0, 0, 0].
• By Step 1, A1 is set at 1 and A4 is set at 0. Best combination becomes
[1, 0, 0, 0, 0].
• By Step 2 (a – c), sign vector for the interaction A2A3 is (1,−1,−1), and the
sign vector for the interaction A3A5 is (1, 1, 1).
• Step 3 applied to the interaction A2A3 sets A2 at 1 and A3 at 0. Best combina-
tion becomes [1, 1, 0, 0, 0].
• Step 3 applied to the interaction A3A5 sets A3 at 1 and A5 at 1. Thus the best
combination becomes [1, 1, 1, 0, 1].
This is an example where the order in which interactions are considered in Algorithm
1 affects the results. Since in our simulations, we considered natural ordering as de-
scribed in Algorithm 1, A3A5 is considered after A2A3. We could have ended up with
a different best combination (e.g., [1, 1, 0, 0, 1]) had we considered A3A5 before A2A3.
Since only the main effect of A1 (but none of its interactions) is significant at the
screening phase, a 2-group follow-up experiment is conducted at the refining phase,
where the 2 groups correspond to the levels 1 and 2 of A1. In both groups, A2, A3,
A4, and A5 are fixed at levels 1, 1, 0, and 1 respectively – as determined by Algorithm
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1 above.
The matlab code for the entire simulation can be found at
http://www.stat.lsa.umich.edu/~bibhas/MOSTcode.html
4.7 Appendix C: Summary Results across Different Simulation Condi-
tions
We conducted a series of simulations in order to investigate whether the results
reported in the main text held across variation along two dimensions: (1) sample
size (N), and (2) number of largest main effects retained in the screening phase as a
decision rule (k). We investigated three different sample sizes: N = 600 (400+200),
1200 (800+400), and 2500 (1600+900); crossed with three different decision rules:
k = 2, 3, and 4 (i.e., nine simulation settings in total). The following three tables
correspond to the three tables in the main text, summarizing across all the nine
settings. In general the classical approach tended to produce a larger E(Y ) than the
MOST approach in small effect size, small sample size conditions; and the MOST
approach tended to produce a larger E(Y ) than the classical approach in medium
or better effect size conditions, even with small sample sizes (N = 600). The MOST
approach tended to produce larger E(Y ) than the classical approach for larger k.
In the conditions in which the four largest main effects were retained, the MOST
approach consistently produced the larger E(Y ), even in the small effect size, small
sample size (N = 600) condition. Details can be seen in the following tables.
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Table 4.4: Whether the Classical (C) or the MOST (M) approach produced the largest value of
E(Y ) under a variety of simulation conditions (This is a summary across 9 simulation
settings of the entries that correspond to the Table 1 in the main text).
k
Sample Size Effect Size k = 2 k = 3 k = 4
600 Small C C M
Medium C M M
Large M M M
1200 Small C C M
Medium M M M
Large M M M
2500 Small C M M
Medium M M M
Large M M M
Table 4.5: Whether the Classical (C) or the MOST (M) approach produced a higher E(Y ) value
in more data sets than its counterpart under a variety of simulation conditions (This is
a summary across 9 simulation settings of the entries that correspond to the Table 2 in
the main text).
k
Sample Size Effect Size k = 2 k = 3 k = 4
600 Small C C M
Medium C M M
Large M M M
1200 Small C C M
Medium M M M
Large M M M
2500 Small C M M
Medium M M M
Large M M M
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Table 4.6: Whether the Classical (C) or the MOST (M) approach showed more accuracy in com-
ponent selection under a variety of simulation conditions (This is a summary across 9
simulation settings of the entries that correspond to the Table 3 in the main text).
k
Dimension Sample Size Effect Size k = 2 k = 3 k = 4
Identifying the correct 600 Small C M M
combination of components Medium M M M
and levels more frequently Large M M M
1200 Small M M M
Medium M M M
Large M M M
2500 Small M M M
Medium M M M
Large M M M
Identifying all the 600 Small C C C
active components Medium C C M
more frequently Large C M M
1200 Small C C C
Medium C C M
Large M M M
2500 Small C C C
Medium M M M
Large M M M
Identifying all the 600 Small M M M
inactive components Medium M M M
more frequently Large M M M
1200 Small M M M
Medium M M M
Large M M M
2500 Small M M M
Medium M M M
Large M M M
CHAPTER V
Inference for Non-regular Parameters in Optimal Dynamic
Treatment Regimes
This chapter provides a detailed treatment of the problem of non-regularity in the
context of optimal dynamic treatment regimes. In the estimation of the optimal dy-
namic treatment regime from longitudinal data, the treatment effect parameters at
any stage prior to the last can be non-regular under certain distributions of the data.
This results in biased estimates and invalid confidence intervals for the treatment ef-
fect parameters. In this chapter, we discuss both the problem of non-regularity, and
available estimation methods. We provide an extensive simulation study to compare
the estimators in terms of their ability to lead to valid confidence intervals under
a variety of non-regular scenarios. Analysis of the smoking cessation trial data is
provided as an illustration.
5.1 Introduction
Many diseases such as mental illnesses, HIV infection, and substance abuse are
clinically treated in multiple stages, adapting the treatment type and dosage to the
ongoing measures of an individual patient’s response, adherence, burden, side effects,
and preference. Dynamic treatment regimes represent one way to operationalize this
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sequential decision making. A dynamic treatment regime (DTR) is a sequence of
decision rules, one per stage. Each decision rule takes a patient’s treatment and
covariate history as input, and outputs a recommended treatment. The main mo-
tivations for considering sequences of treatments are high variability across patients
in response to any one type of treatment, likely relapse, presence or emergence of
co-morbidities, time-varying side effect severity, and reduction of costs and burden
when intensive treatment is unnecessary [24].
A DTR is said to be optimal if it optimizes the mean outcome at the end of the
final stage of treatment. Data for estimating the optimal DTR can come from either
an observational longitudinal study or a sequential multiple assignment randomized
trial (SMART) [49, 50, 32, 57]. In these designs, each patient is followed through
stages of treatment and at each stage the patient is randomized to one of the possible
treatment options. Experimental designs similar to SMART have been implemented
in the treatments of schizophrenia [81], depression [78], and cancer [93, 99].
Estimating the optimal DTR is a problem of sequential, multi-stage decision mak-
ing. Murphy [56] developed a semiparametric method for estimating the optimal
DTR, an efficient version of which was provided by Robins [71]. A good discussion
of the relationship between these two methods can be found in Moodie et al. [55].
Other methods for estimating optimal DTRs in the literature include likelihood-
based methods, both frequentist and Bayesian, developed by Thall et al. [93, 94, 95],
and the semiparametric methods of Lunceford et al. [51], and Wahed and Tsiatis
[99, 100].
Robins [71] considered the problem of inference for the parameters of the optimal
DTR. As discussed by Robins, the treatment effect parameters at any stage prior
to the last can be non-regular under certain longitudinal distributions of the data
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which he called exceptional laws. By non-regularity, we mean that the asymptotic
distribution of the estimator of the treatment effect parameter does not converge
uniformly over the parameter space (see below for further details). This phenomenon
of non-regularity causes bias in estimation, and leads to poor frequentist properties
of the confidence intervals. Recently Moodie and Richardson [54] provided a method
called Zeroing Instead of Plugging In (ZIPI) for correcting the bias in the estimation
of the optimal DTRs resulting under exceptional laws.
The main goals of this chapter are to illustrate the problem of non-regularity, and
to compare available estimation methods that attempt to address this problem. In
section 5.2, we discuss the problem of non-regularity in detail. Section 5.3 provides a
description of different methods that address the problem. We provide an extensive
simulation study in section 5.4 to compare the estimators in terms of their ability to
lead to valid confidence intervals using bootstrap. This is followed by an analysis of
a data set from a longitudinal smoking cessation trial in section 5.5; the purpose is
to demonstrate the applicability of the estimation methods in a real-life non-regular
scenario. Finally an overall discussion is provided in section 5.6. Throughout this
chapter, we assume that the data come from SMART designs. The main reason for
this is to separate the issue of non-regularity from causal inference issues. However
the problem of non-regularity also arises when observational data are used [71, 54];
and the estimators proposed in section 5.3 should be applicable to observational data
as well. Technical details are presented in the appendices at the end of the chapter.
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5.2 Estimation and Inference via Q-learning
5.2.1 Notation and Data Structure
For simplicity, we focus on studies with two stages. Longitudinal data on a single
patient are given by the trajectory (O1, A1, O2, A2, O3), where Oj (j = 1, 2) denotes
the covariates measured prior to treatment at the beginning of the j-th stage, O3 is
the observation at the end of stage 2, and Aj (j = 1, 2) is the treatment assigned at
the j-th stage subsequent to observing Oj. The data set consists of a random sample
of n patients. Define the history at each stage as: H1 = O1, H2 = (O1, A1, O2). We
consider a SMART design in which there are two possible treatments at each stage,
Aj ∈ {−1, 1}; here we assume P [Aj = −1|Hj] = P [Aj = 1|Hj] = 12 . The study
can have either a single primary outcome Y observed at the end of stage 2, or two
outcomes Y1, Y2 observed at the two stages. Note that the case of a single outcome
Y observed at the end can be viewed as a case with Y1 ≡ 0 and Y2 = Y . We assume
Y1 = f1(O1, A1, O2) and Y2 = f2(O1, A1, O2, A2, O3), with known functions f1, f2. A
two-stage DTR consists of two decision rules, say (d1, d2), with dj(Hj) ∈ Aj, where
Aj is the set of possible treatments at the j-th stage.
One simple method to construct (d1, d2) is Q-learning [101, 90, 58]. Q-learning,
like Robins’ g-estimation of optimal structural nested mean models (hereafter simply
referred to as Robins’ method), suffers from non-regularity – the common reason
being an underlying non-smooth maximization operation. Here we will illustrate the
problem due to non-regularity using Q-learning, since it can be viewed as a gener-
alization of the least squares regression to multistage decision problems, and hence
simpler to explain than Robins’ semiparametric efficient method. In Lemma V.1
below, we provide conditions under which Q-learning is equivalent to an inefficient
version of Robins’ method.
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5.2.2 Q-learning with Linear Models
First let us define the Q-functions [90, 58] for the two stages as follows:












If the two Q-functions were known, the optimal DTR (d1, d2), using backwards in-
duction (as in dynamic programming) argument, would be
dj(hj) = arg max
aj
Qj(hj, aj), j = 1, 2.(5.1)
In practice, the true Q-functions are not known and hence must be estimated from
the data. Consider a linear model for the Q-functions. Let the stage-j (j = 1, 2)
Q-function be modeled as
Qj(Hj, Aj; βj, ψj) = β
T
j Hj0 + (ψ
T
j Hj1)Aj,(5.2)
where Hj0 and Hj1 are two (possibly different) summaries of the history Hj, with
Hj0 denoting the “main effect of history” and Hj1 denoting the part of history that
interacts with treatment (Hj0 and Hj1 include the intercept term). The Q-learning
algorithm is:






Y2i−Q2(H2i, A2i; β2, ψ2)
)2
.
2. Stage-2 optimal rule: d̂2(h2) = arg maxa2 Q2(h2, a2; β̂2, ψ̂2).
3. Stage-1 pseudo-outcome: Ŷ1i = Y1i + maxa2 Q2(H2i, a2; β̂2, ψ̂2), i = 1, . . . , n.






Ŷ1i−Q1(H1i, A1i; β1, ψ1)
)2
.
5. Stage-1 optimal rule: d̂1(h1) = arg maxa1 Q1(h1, a1; β̂1, ψ̂1).
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The estimated optimal DTR using Q-learning is given by (d̂1, d̂2).
The following lemma gives a set of sufficient conditions under which Q-learning is
equivalent to an inefficient version of Robins’ method.
Lemma V.1. Consider linear models for the Q-functions as in (5.2). Assume that:
(i) the parameters in Q1 and Q2 are distinct;
(ii) Aj has zero conditional mean given the history Hj, j = 1, 2; and
(iii) the covariates used in the model for Q1 are nested within the covariates used in





Then Q-learning is algebraically equivalent to an inefficient version of Robins’ method.
The proof is given in Appendix A.
5.2.3 The Inference Problem
With (5.2) as the model for Q-functions, the optimal DTR is given by
dj(Hj) = arg max
aj
(ψTj Hj1)aj = sign(ψ
T
j Hj1), j = 1, 2,(5.3)
where sign(x) = 1 if x > 0, and −1 otherwise. Note that the term βTj Hj0 on the
right side of (5.2) does not feature in the optimal DTR. Thus for estimating optimal
DTRs, the ψj’s are the parameters of interest, while βj’s are nuisance parameters.
We want to perform inference (e.g., construct confidence intervals) on ψj’s.
Conducting inference on ψj’s is important for the following reasons. First, if the
confidence intervals (or hypothesis tests) for ψj reveal that there is evidence that
some components of the parameter vector ψj are not clinically different from zero,
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then the investigator may choose not to collect the corresponding components of the
history vector Hj1 while making decisions using the optimal DTR. This reduces the
cost of data collection in a future implementation of the optimal DTR. Thus in the
present context, confidence intervals (or hypothesis tests) can be viewed as a tool for
doing variable selection. Second, it is important to know when there is insufficient
support in the data to recommend one treatment over another, since in such cases
treatment can be chosen according to other considerations like cost, familiarity, bur-
den, preference etc. Third, as discussed by Robins [71], confidence intervals for ψj
can lead to confidence intervals for dj. In the following, we discuss the problem of
non-regularity in inference.
5.2.4 Non-regularity in Inference
Note that the stage-1 pseudo-outcome (in the Q-learning algorithm) is
Ŷ1i = Y1i + max
a2
Q2(H2i, a2; β̂2, ψ̂2) = Y1i + β̂
T
2 H20,i + |ψ̂T2 H21,i|,(5.4)
which is a non-smooth (e.g., non-differentiable at ψ̂T2 H21,i = 0) function of ψ̂2, be-
cause of the maximization operation. Since ψ̂1 is a function of Ŷ1i, i = 1, . . . , n, it
is in turn a non-smooth function of ψ̂2. As a consequence, the asymptotic distribu-
tion of
√
n(ψ̂1 − ψ1) does not converge uniformly [71] over the parameter space of
ψ = (ψ1, ψ2). More specifically, the asymptotic distribution of
√
n(ψ̂1−ψ1) is normal
if ψ2 is such that P [H2 : ψ
T
2 H21 = 0] = 0, but is non-normal if P [H2 : ψ
T
2 H21 = 0] > 0.
This change in the asymptotic distribution happens abruptly. The (vector) parame-
ter ψ1 is called a non-regular parameter and the estimator ψ̂1 is called a non-regular
estimator; see [5] for the precise definition of non-regularity. Because of this non-
regularity, given the noise level present in small samples, the estimator ψ̂1 oscillates
103
between the two asymptotic distributions across samples. As a result, usual Wald
type confidence intervals perform poorly [71, 54].
The issue of non-regularity can be better understood with a toy example discussed
by Robins [71] (here is a slightly modified version). Consider the problem of esti-
mating |µ| based on n i.i.d. observations X1, . . . , Xn from N(µ, 1). Note that |X̄n|
is the maximum likelihood estimator of |µ|, where X̄n is the sample average. It can
be shown that the asymptotic distribution of
√
n(|X̄n| − |µ|) for µ = 0 is different
from that for µ 6= 0. Thus |X̄n| is a non-regular estimator of |µ|. Also, for µ = 0,
limn→∞ E[
√




. Robins referred to this quantity as the asymptotic
bias of the estimator |X̄n|. This asymptotic bias is one symptom of the underlying
non-regularity, as discussed by Moodie and Richardson [54].
In many situations where the asymptotic distribution of an estimator is unavail-
able, bootstrap is used as an alternative approach to conduct inference. But the
success of bootstrap also hinges on the underlying smoothness of the estimator.
When an estimator is non-smooth, the ordinary (n out of n) bootstrap procedure
produces an inconsistent bootstrap estimator [84]. Inconsistency of bootstrap in the
above simple normal theory example has been discussed by Andrews [2]. As shown
by Shao [84], an alternative resampling procedure called “m out of n bootstrap”
is consistent in such non-smooth scenarios. One concern regarding the use of this
procedure is the slower rate of convergence than
√
n even in a regular setting (e.g.,
when P [H2 : ψ
T
2 H21 = 0] = 0). Moreover, a data-adaptive choice of the tuning
parameter m in the present context of DTRs is not obvious; see however [6] and [43]
for data-adaptive choice of m in other contexts.
The above concerns regarding non-regularity led us to investigate possible reg-
ularizations of the estimation procedure, and then use bootstrap for inference. In
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the simulation study to follow, we will investigate the behavior of different types of
bootstrap confidence intervals for the parameters ψj of the optimal DTR in both
regular and non-regular settings.
5.3 Different Regularized Estimators
In this section, we will present two competing estimators to address the non-
regularity problem described above. Limited theoretical results are available at this
point, and consequently it is not clear which estimator is better. In this chapter, we
will study their relative merits and demerits in simulations.
From the discussion on non-regularity above, it is clear that ψ̂1 is a non-regular
estimator because the stage-1 pseudo-outcome Ŷ1 is a non-smooth function (e.g.,
absolute value) of ψ̂2. The estimators presented in this section “regularize” the
non-regular estimator (sometimes called the “hard-max” estimator because of the
maximum operation used in the definition) by shrinking or thresholding the effect of
the term involving the maximum, e.g., |ψ̂T2 H21|, towards zero.
5.3.1 Hard-threshold Estimator
Recall that the pseudo-outcome Ŷ1 = Y1 + β̂
T
2 H20 + |ψ̂T2 H21| is non-differentiable
in ψ̂2 only when ψ̂
T
2 H21 = 0, and so the corresponding estimator ψ̂1 is problematic
only when the true ψT2 H21 is close to zero. The general form of the hard-threshold
pseudo-outcome is
Ŷ HT1i = Y1i + β̂
T
2 H20,i + |ψ̂T2 H21,i| · 1{|ψ̂T2 H21,i| > λi},(5.5)
where λi (> 0) is the threshold for the i-th subject in the sample (possibly depending
on the variability of the linear combination ψ̂T2 H21,i for that subject). One way to
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operationalize this is to perform a preliminary test (for each subject in the sample)
of the hypothesis H0i : ψ
T
2 H21,i = 0 (H21,i is considered fixed in this test), set
Ŷ HT1i = Ŷ1i if H0i is rejected, and replace |ψ̂T2 H21,i| with the “better guess” 0 in case
H0i is accepted. Thus the hard-threshold pseudo-outcome can be written as
Ŷ HT1i = Y1i + β̂
T







where Σ̂2 is the estimated covariance matrix of ψ̂2. The corresponding estimator
of ψ1, denoted by ψ̂
HT
1 , will be referred to as the hard-threshold estimator. The
hard-threshold estimator is common in many areas like variable selection in linear
regression and wavelet shrinkage [34]. Moodie and Richardson [54] proposed this
estimator for bias correction in the context of Robins’ method, and called it Zeroing
Instead of Plugging In (ZIPI) estimator.
Note that Ŷ HT1 is still a non-smooth function of ψ̂2 and hence ψ̂
HT
1 is a non-regular
estimator of ψ1. However, the problematic term |ψ̂T2 H21| is shrunk (thresholded) to-
wards zero, and hence one might expect that the degree of non-regularity is somewhat
reduced. Moodie and Richardson[54] showed that this estimator reduces the bias oc-
curring in Robins’ method (efficient version of Q-learning). In the simulation study
to follow, we will explore if this estimator can be used to construct valid confidence
intervals for ψ1. An important issue regarding the use of this estimator is the choice
of significance level α of the preliminary test, which is an unknown tuning param-
eter. As discussed by Moodie and Richardson[54], this is a difficult problem even
in better-understood settings where preliminary test based estimators are used; and
no widely applicable data-driven method for choosing α in this setting is currently
available.
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5.3.2 Soft-threshold or Shrinkage Estimator
The general form of the soft-threshold pseudo-outcome considered here is
Ŷ ST1i = Y1i + β̂
T





where x+ = x1{x > 0} stands for the positive part of a function, and λi (> 0) is
a tuning parameter associated with the i-th subject in the sample (again possibly
depending on the variability of the linear combination ψ̂T2 H21,i for that subject). In
the contexts of regression shrinkage [12] and wavelet shrinkage [40], the third term
in (5.7) is generally known as the nonnegative garrote estimator. As discussed by
Zou [109], the nonnegative garrote estimator is a special case of the adaptive lasso
estimator. As in the case of hard-threshold estimator, a crucial issue here is to choose
a data-driven tuning parameter λi. Below we provide a choice following a Bayesian
approach.
Like the hard-threshold pseudo-outcome, Ŷ ST1 is also a non-smooth function of ψ̂2
and hence ψ̂ST1 remains a non-regular estimator of ψ1. However, the problematic term
|ψ̂T2 H21| is shrunk (or thresholded) towards zero, and hence one might expect that
the degree of non-regularity is somewhat reduced. In the simulation study to follow,
we will investigate how much improvement this estimator offers over the “hard-max”
estimator, when it comes to constructing confidence intervals. Figure 1 presents the
hard-max, the hard-threshold, and the soft-threshold pseudo-outcomes.
Choice of Tuning Parameter
A hierarchical Bayesian formulation of the problem, inspired by the work of
Figueiredo and Nowak [35] in the area of wavelet-based image processing, can be
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used in the context of the soft-threshold estimator to choose λi’s in a data-driven
way. It turns out that the estimator (5.7) with λi = 3H
T
21,iΣ̂2H21,i/n, i = 1, . . . , n,
where Σ̂2/n is the estimated covariance matrix of ψ̂2, is an approximate empirical
Bayes estimator. The following lemma will be used to derive the choice of λi.
Lemma V.2. Let X be a random variable such that X|µ ∼ N(µ, σ2) with known
variance σ2. Let the prior distribution on µ be given by µ|φ2 ∼ N(0, φ2), with
Jeffrey’s noninformative hyper-prior on φ2, e.g., p(φ2) ∝ 1/φ2. Then an empirical






































where Φ(·) is the standard normal distribution function.
The proof is given in Appendix B.















































































≈ (2 I{X>0} − 1) = sign(X).














Now for i = 1, . . . , n separately, put X = ψ̂T2 H21,i, and µ = ψ
T
2 H21,i (for fixed
H21,i); and plug in σ̂
2 = HT21,iΣ̂2H21,i/n for σ
2. This leads to a choice of λi in the
soft-threshold pseudo-outcome (5.7):
Ŷ ST1i = Y1i + β̂
T








= Y1i + β̂
T
















i = 1, . . . , n.(5.10)
The presence of the indicator function in (5.10) indicates that Ŷ ST1i is a thresholding
rule for small values of |ψ̂T2 H21,i|, while the term just preceding the indicator function
makes Ŷ ST1i a shrinkage rule for moderate to large values of |ψ̂T2 H21,i| (for which the
indicator function takes the value one). Thus the current Bayesian formulation gives
us a data-driven choice of the tuning parameters.
5.4 Simulation Study
In this section, we consider a simulation study to compare the performances of
the hard-max, the hard-threshold, and the soft-threshold estimators under different
non-regular scenarios. In this study, we vary the parameters of the generative model,
the degree of non-regularity, and the type of bootstrap confidence interval.
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Generative Model
Recall that the data consist of n patient trajectories. Each such trajectory is of
the form (O1, A1, O2, A2, O3). Without loss of generality, we assume Y1 ≡ 0 and
Y2 ≡ Y = O3. Let µY = E[Y |O1, A1, O2, A2], and ε be the associated error term.
Then Y = µY + ε, where
µY = γ1 + γ2O1 + γ3A1 + γ4O1A1 + γ5A2 + γ6O2A2 + γ7A1A2,
and ε ∼ N(0, 1). Next, we consider binary treatments randomized with probability
1/2, e.g., P [Aj = 1] = P [Aj = −1] = 1/2, j = 1, 2. Also, the binary covariates Oj’s
are generated as
P [O1 = 1] = P [O1 = −1] = 1/2,
P [O2 = 1|O1, A1] = 1− P [O2 = −1|O1, A1] = expit(δ1O1 + δ2A1),
where expit(x) = exp(x)/(1 + exp(x)). Note that γ1, . . . , γ7 and δ1, δ2 are the pa-
rameters that specify the generative model. These parameters will be varied in the
examples to follow.
Analysis Model
Q2(H2, A2) = β20 + β21O1 + β22A1 + β23O1A1 +
(
ψ20 + ψ21O2 + ψ22A1
)
A2,





Two dimensions of non-regularity: p and φ
Non-regularity in stage 1 parameters arises when the optimal stage 2 treatment is
non-unique for at least some subjects in the population. With reference to the present
generative model, a setting is non-regular if the linear combination γ5+γ6O2+γ7A1 =
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Table 5.1: Distribution of the linear combination (γ5 + γ6O2 + γ7A1)
(O2, A1) cell cell probability value of the
(averaged over O1) linear combination
(1, 1) q1 ≡ 14
(
expit(δ1 + δ2) + expit(−δ1 + δ2)
)
f1 ≡ γ5 + γ6 + γ7
(1,−1) q2 ≡ 14
(
expit(δ1 − δ2) + expit(−δ1 − δ2)
)
f2 ≡ γ5 + γ6 − γ7
(−1, 1) q3 ≡ 14
(
expit(δ1 − δ2) + expit(−δ1 − δ2)
)
f3 ≡ γ5 − γ6 + γ7
(−1,−1) q4 ≡ 14
(
expit(δ1 + δ2) + expit(−δ1 + δ2)
)
f4 ≡ γ5 − γ6 − γ7
0 with positive probability. Also one might expect some non-regular behavior as
γ5 + γ6O2 + γ7A1 falls in a small neighborhood of zero (even though not exactly
zero). In the following, we consider specific examples varying the “degree of non-
regularity”, e.g., p = P [γ5 + γ6O2 + γ7A1 = 0] and the “standardized effect size”
defined as φ =
∣∣∣E[γ5 + γ6O2 + γ7A1]/
√
V ar[γ5 + γ6O2 + γ7A1]
∣∣∣. The quantities p
and φ, which depend on the distribution of the above linear combination, represent
two dimensions of the non-regularity phenomenon. Note that the linear combination
(γ5 + γ6O2 + γ7A1) can take only four possible values corresponding to the four
possible (O2, A1) cells. The cell probabilities can be easily calculated; the formulae
are provided in Table 5.1.










4 , where q1, . . . , q4 are the cell probabilities given in
Table 1. From these two, one can calculate V ar[γ5 +γ6O2 +γ7A1], and subsequently
the effect size φ.
We want to conduct inference on ψ10 and ψ11, the analysis model parameters
associated with stage 1 treatment A1. They can be expressed in terms of γ’s and δ’s,
the parameters of the generative model, as follows. It turns out that
ψ10 = γ3 + q1|f1| − q2|f2|+ q3|f3| − q4|f4|,
and ψ11 = γ4 + q
′
1|f1| − q′2|f2| − q′3|f3|+ q′4|f4|,
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(expit(δ1 + δ2)− expit(−δ1 + δ2)), and q′2 = q′4 = 14(expit(δ1− δ2)−
expit(−δ1− δ2)). In the following, we consider specific examples for varying p and φ.
In Examples 1− 4 below, we use δ1 = δ2 = 0.5. For this choice, we get the following
values of the cell probabilities: q1 = q4 = 0.3078 and q2 = q3 = 0.1922. This choice







Example 1 (p = 1, φ undefined): Consider a setting where there is no treatment
effect for any subject (any history) in either stage. This is achieved by setting
γ1 = . . . = γ7 = 0, and δ1 = δ2 = 0.5. Then f1 = f2 = f3 = f4 = 0, and hence
ψ10 = ψ11 = 0, p = 1, and φ is undefined (0/0). This is a fully non-regular scenario.
Example 2 (p = 0, φ infinite): Consider a setting similar to Example 1, where there
is a very weak stage 2 treatment effect for every subject (all possible history). This
is achieved by setting γ5 = 0.01 and γj = 0,∀j 6= 5, and δ1 = δ2 = 0.5. Then
f1 = f2 = f3 = f4 = 0.01; ψ10 = ψ11 = 0, p = 0, and φ is infinite (0.01/0). This is a
regular scenario, but close to non-regularity (it is hard to detect the very weak effect
given the noise level in the data).
Example 3 (p = 1
2
, φ = 1): Consider a setting where there is no stage 2 treatment
effect for half the subjects in the population, but a reasonably large effect for the
other half of subjects. This is achieved by setting γ1 = γ2 = γ4 = γ6 = 0, γ3 = −0.5,
γ5 = γ7 = 0.5, and δ1 = δ2 = 0.5. Then f1 = f3 = 1, f2 = f4 = 0, ψ10 = ψ11 = 0,
p = 1
2
and φ = 1. This is a non-regular setting.
Example 4 (p = 0, φ = 1.0204): Consider a setting where there is a very weak stage 2
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treatment effect for half the subjects in the population, but a reasonably large effect
for the other half of subjects. This is achieved by setting γ1 = γ2 = γ4 = γ6 = 0,
γ3 = −0.5, γ5 = 0.5, γ7 = 0.49, and δ1 = δ2 = 0.5. It follows that f1 = f3 = 0.99,
f2 = f4 = 0.01, ψ10 = −0.0100, ψ11 = 0, p = 0, and φ = 1.0204. This regular
example is close to the non-regular Example 3.
Example 5 (p = 1
4
, φ = 1.4142): Consider a setting where there is no stage 2
treatment effect for one-fourth of the subjects in the population, but others have a
reasonably large effect. To achieve this, set γ1 = γ2 = γ4 = 0, γ3 = −0.5, γ5 = 1,
γ6 = γ7 = 0.5, δ1 = 1, and δ2 = 0. Then f1 = 2, f2 = f3 = 1, f4 = 0; the cell
probabilities are equal, i.e., q1 = q2 = q3 = q4 =
1
4







Consequently, ψ10 = ψ11 = 0, p =
1
4
, and φ = 1.4142. This is a non-regular setting.
Example 6 (p = 0, φ = 0.3451): Consider a completely regular setting where there is
a reasonably large stage 2 treatment effect for every subject in the population. This
can be achieved by setting γ1 = γ2 = γ4 = 0, γ3 = −0.5, γ5 = 0.25, γ6 = γ7 = 0.5,
and δ1 = δ2 = 0.1. Then f1 = 1.25, f2 = f3 = 0.25, and f4 = −0.75; the cell









It follows that ψ10 = −0.3688, ψ11 = 0.0187, p = 0 and φ = 0.3451.
Note that in Example 5, the effect size φ is greater than Cohen’s [21] benchmark
large effect size (=0.8). Such a high effect size can be criticized as being unrealistic,
based on the principle of clinical equipoise [38], which provides the ethical basis for
medical research involving randomization. This principle says that there must be
a honest, professional disagreement (high variability) among expert clinicians about
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the preferred treatment (and thus the standardized effect size of treatment is likely
small). Hence this example might be somewhat down-weighted for overall compar-
ison of performance. Furthermore, Example 6 violates the Hierarchical Ordering
Principle [107] in that the coefficient of the interaction term A1A2 (γ7) is larger than
the coefficient of the main effect A2 (γ5). So this example might be given lower
weight as well.
Competing Estimators
In the simulation, we will consider four estimators: the hard-max estimator (orig-
inal Q-learning), the soft-threshold estimator, and the hard-threshold estimator with
two values of the tuning parameter α, e.g., 0.2, which was empirically found to be
a good choice by Moodie and Richardson [54], and 0.08 which corresponds to the
threshold used by the soft-threshold estimator proposed in this paper (from (5.10),
the threshold used by the soft-threshold estimator is
√
3 = 1.7321; equating this
point to zα/2 and solving for α, we get α = 0.0833).
Different Bootstrap CIs
We consider three types of bootstrap CIs, e.g., percentile, hybrid, and double
(percentile) bootstrap CIs. Let θ̂ be an estimator of θ and θ̂∗ be its bootstrap version.




















θ̂∗γ is the 100γ-th percentile of the bootstrap distribution. The double bootstrap (DB)
CI is calculated as follows:
1. Draw B1 first-stage bootstrap samples from the original data. For each first-
stage bootstrap sample, calculate the bootstrap version of the estimator θ̂∗b,
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b = 1, . . . , B1.
2. Conditional on each first-stage bootstrap sample, draw B2 second-stage (nested)
bootstrap samples and calculate the double bootstrap versions of the estimator,
e.g., θ̂∗∗bm, b = 1, . . . , B1, m = 1, . . . , B2.




m=1 1{θ̂∗∗bm ≤ θ̂}, where θ̂ is the esti-
mator based on the original data.










, where q̂(γ) = u∗(γ), the
100γ-th percentile of the distribution of u∗b, b = 1, . . . , B1.
See [31] and [63] for details about double bootstrap CIs. One disadvantage of these
CIs is that they are computationally very intensive.
We use B = 1000 bootstrap iterations to calculate the percentile and the hybrid
bootstrap CIs. However, the double bootstrap CIs are based on B1 = 500 first-stage
and B2 = 100 second-stage bootstrap iterations (due to the increased computational
burden). The results in Tables 5.2− 5.3 are based on N = 1000 Monte Carlo itera-
tions.
5.4.1 Results
The simulation study compares the competing estimators on a variety of settings
represented by Examples 1−6. We considered estimation and inference for both ψ10
and ψ11. However in the present examples, the effect of non-regularity turned out to
be more pronounced for the parameter ψ10 (main effect of A1) than ψ11 (interaction
of A1 with O1). Hence we included results on ψ10 only in Tables 5.2 and 5.3. Also
in the following discussion, we will focus on ψ10.
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In Example 1 (top part of Table 5.2), where stage 2 effects for all possible histories
are zero (i.e., the stage 2 optimal treatment is non-unique for every subject in the
population), we see that there is no bias associated with the hard-max estimator;
and the mean squared error (MSE) is essentially the same as the variance. However
the percentile bootstrap CI (both 95% and 90%) has over-coverage (note that over-
coverage translates to lower power of the corresponding hypothesis test), and the
hybrid bootstrap CI (95%) has under-coverage compared to the nominal level. We
have also studied the Wald type CIs for this setting (not included in this paper) and
observed over-coverage; the problem with Wald type CIs in such non-regular settings
is well-known [71, 54]. This suggests that the asymptotic distribution of the hard-
max estimator has a lighter tail than a comparable normal distribution. However,
the double bootstrap CIs have correct coverage. Note that both versions of the hard-
threshold estimator fail to rectify the coverage rate, even though neither suffer from
bias. However, the soft-threshold estimator offers correct coverage for both types of
bootstrap CIs. Moreover, it gives the lowest MSE among the four estimators. Note
that the soft-threshold estimator is also non-smooth (non-regular), and consequently
the bootstrap distribution is inconsistent for the true asymptotic distribution of this
estimator. But in this setting, it reduces the degree of non-regularity just enough so
that the bootstrap CIs do not show the problem with coverage.
Even though Example 2 (middle part of Table 5.2) is a regular setting (p = 0), it
is very close to Example 1 and hence affected by non-regularity. Results are similar
to those in Example 1. Thus the presence of very small effects causes problems with
coverage even in regular settings.
Example 3 (bottom part of Table 5.2) is a setting where the stage 2 optimal treat-
ment is non-unique for half the subjects in the population (p = 1
2
) and is unique for
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the remaining half, but the overall standardized stage 2 effect size φ (= 1) is quite
large. Here the hard-max estimator is biased, and hence both the percentile and
the hybrid bootstrap CIs under-cover the true value. However the double bootstrap
CI gives correct coverage rate. Both versions of the hard-threshold estimator reduce
bias and one of them (corresponding to α = 0.08) gives correct coverage, while the
other also offers substantial improvement of the coverage rate. This is consistent
with the findings of [54]. The soft-threshold estimator also reduces bias, gives the
lowest MSE among the four estimators, and provides correct coverage with the hy-
brid bootstrap method but not with the percentile method (even though it offers
substantial improvement). Thus in this example, the hard-threshold estimator with
α = 0.08 emerges as the winner, with the soft-threshold estimator at the second
place. However, note that the value 0.08 of the tuning parameter α is not arbitrary –
it corresponds to the threshold used by the soft-threshold estimator. If constructing
Table 5.2: Summary statistics and coverage rates of 95% and 90% nominal percentile (PB), hybrid
(HB), and double (DB) bootstrap CIs for ψ10 using the hard-max (HM), the hard-
threshold with α = 0.08 (HT0.08) and α = 0.2 (HT0.20), and the soft-threshold (ST)
estimators. A “*” indicates significantly different coverage rate than the nominal rate,
using a test of proportion (Type I error rate = 0.05).
Summary Statistics Coverage of 95% CI Coverage of 90% CI
Estimator Bias Var MSE PB HB DB PB HB DB
Example 1: p = 1 and φ undefined (ψ10 = ψ11 = 0)
HM 0.0003 0.0045 0.0045 96.8* 93.5* 93.6 92.9* 88.2 88.8
HT0.08 0.0017 0.0044 0.0044 97.0* 95.0 – 93.7* 90.3 –
HT0.20 0.0002 0.0050 0.0050 97.4* 92.8* – 94.2* 86.9* –
ST 0.0009 0.0036 0.0036 95.3 96.1 – 91.1 91.4 –
Example 2: p = 0 and φ infinite (ψ10 = ψ11 = 0)
HM 0.0003 0.0045 0.0045 96.7* 93.4* 93.6 92.4* 88.2 89.0
HT0.08 0.0010 0.0044 0.0044 97.1* 95.3 – 94.0* 90.5 –
HT0.20 0.0003 0.0050 0.0050 97.3* 93.5* – 94.3* 87.1* –
ST 0.0008 0.0036 0.0036 95.4 95.9 – 90.8 91.5 –
Example 3: p = 12 and φ = 1 (ψ10 = ψ11 = 0)
HM -0.0401 0.0059 0.0075 88.4* 92.7* 94.8 81.2* 86.1* 89.0
HT0.08 -0.0083 0.0058 0.0059 94.3 94.3 – 88.5 89.0 –
HT0.20 -0.0179 0.0062 0.0065 93.5* 93.5* – 87.0* 88.1* –
ST -0.0185 0.0055 0.0058 93.4* 94.9 – 87.1* 89.4 –
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confidence intervals is the main goal (so biased estimation is less of an issue), double
bootstrap CI along with the hard-max estimator can also be used in this setting,
although it is computationally more expensive.
Example 4 (top part of Table 5.3) is a regular setting, very similar to the non-
regular setting in Example 3. Results are quite similar to those in Example 3. This
is consistent with our previous observation (Example 2) that the presence of very
small effects causes problems with coverage even in regular settings.
In example 5 (middle part of Table 5.3), the stage 2 optimal treatment is non-
unique for one-fourth of the subjects in the population (p = 1
4
) and the standardized
effect size φ is very large (=1.4142). Again, the hard-max estimator is biased, and
has low coverage of the CIs (except for double bootstrap). The hard-threshold and
the soft-threshold estimators offer improvement in terms of bias as well as coverage.
The soft-threshold estimator emerges as the best (lowest MSE and correct coverage
rate) in this example.
Example 6 (bottom part of Table 5.3) is a regular setting (p = 0, with no extremely
tiny stage 2 effect as in Examples 2 and 4), with the standardized effect size 0.3451.
The reason for investigating this setting is to check if the regularized estimators (hard
and soft threshold) perform poorly in settings where there is no need to regularize. As
expected, the hard-max estimator performs well here. The soft-threshold estimator
introduces some bias when there is none in the hard-max estimator and increases
MSE; but still manages to provide correct coverage for the percentile bootstrap
method. The hard-threshold estimators also give correct coverage for percentile CIs.
To summarize, the hard-max estimator is problematic in non-regular scenarios,
except when used with the computationally intensive double bootstrap method for
constructing confidence intervals. The hard-threshold estimator, if properly tuned,
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addresses the problem of bias but not the problem of light tail. The soft-threshold
estimator seems to address both problems to a large extent. In the simulation, the
soft-threshold estimator consistently produced the lowest MSE among the competing
methods across all the non-regular scenarios. Also in all the non-regular settings, ei-
ther the soft-threshold estimator or the hard-threshold estimator with α = 0.08 (this
α corresponds to the threshold used by the soft-threshold estimator) emerged as the
winner in terms of providing correct coverage rate of the bootstrap CIs. Even though
the soft-threshold estimator incurs some bias in regular settings, it manages to pro-
vide reasonable coverage rate for small to moderate standardized effect sizes (we
have studied up to around 0.35). Across all the scenarios considered here (Examples
1− 6), the soft-threshold estimator emerged as more robust than the hard-threshold
estimator to the degree of regularity of the underlying data distribution, probably
because of its “soft” nature (the soft-threshold estimator is continuous everywhere
Table 5.3: Summary statistics and coverage rates of 95% and 90% nominal percentile (PB), hybrid
(HB), and double (DB) bootstrap CIs for ψ10 using hard-max (HM), hard-threshold
with α = 0.08 (HT0.08) and α = 0.2 (HT0.20), and soft-threshold (ST) estimators. A
“*” indicates significantly different coverage rate than the nominal rate, using a test of
proportion (Type I error rate = 0.05).
Summary Statistics Coverage of 95% CI Coverage of 90% CI
Estimator Bias Var MSE PB HB DB PB HB DB
Example 4: p = 0 and φ = 1.0204 (ψ10 = −0.01, ψ11 = 0)
HM -0.0353 0.0059 0.0072 89.6* 93.1* 94.4 82.9* 86.6* 90.2
HT0.08 -0.0037 0.0058 0.0058 94.6 94.1 – 88.9 89.0 –
HT0.20 -0.0130 0.0062 0.0064 93.9 92.8* – 87.9* 87.9* –
ST -0.0138 0.0055 0.0057 94.1 95.0 – 87.4* 89.7 –
Example 5: p = 14 and φ = 1.4142 (ψ10 = ψ11 = 0)
HM -0.0209 0.0069 0.0074 92.7* 93.1* 94.2 87.8* 89.0 88.4
HT0.08 -0.0059 0.0070 0.0071 93.9 93.2* – 89.5 88.2 –
HT0.20 -0.0101 0.0072 0.0073 93.3* 93.0* – 89.3 88.0* –
ST -0.0065 0.0069 0.0069 93.8 94.6 – 89.7 89.0 –
Example 6: p = 0 and φ = 0.3451 (ψ10 = −0.3688, ψ11 = 0.0187)
HM 0.0009 0.0067 0.0067 95.0 93.8 95.0 89.2 87.4* 88.2
HT0.08 0.0003 0.0081 0.0081 95.1 88.5* – 90.1 82.9* –
HT0.20 0.0011 0.0074 0.0074 94.8 91.2* – 89.7 86.4* –
ST 0.0052 0.0074 0.0074 94.8 91.7* – 89.4 85.3* –
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even though it has two points of non-differentiability, whereas the hard-threshold
estimator has two points of discontinuity – see Figure 5.1). Furthermore, note that
overall the hybrid bootstrap CIs performed slightly better than the percentile boot-
strap CIs in this simulation study. Hence the hybrid bootstrap CIs will be used in
the data analysis to follow.
5.5 Analysis of the Smoking Cessation Data
To demonstrate the occurrence of non-regularity and the use of the soft-threshold
method in a real application, here we present the analysis (two versions) of a data set
from a randomized, two-stage, longitudinal, internet-based smoking cessation study
described in chapter II. The stage 1 of this study (Project Quit) was conducted to
find an optimal multicomponent behavioral intervention to help adult smokers quit
smoking; and the stage 2 (Forever Free) was a follow-on study to help those (among
the participants of Project Quit) who already quit stay quit, and help those who
failed at the previous stage with a second chance. Details of the study design and
primary analysis of the stage 1 data can be found in [88]; see also chapter II. In
section 5.5.1 we present a complete-case analysis with the primary outcome of the
study, e.g. quit status. However it is well-known that such an analysis can lead to
biased estimates (so called non-response bias). To address this, we present a refined
analysis using multiple imputation (MI) in section 5.5.2. See Appendix C for a brief
review of the MI technique.
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5.5.1 Complete-case Analysis
At stage 1, although there were five two-level treatment factors, only two, e.g.,
source (of online behavioral counseling message) and story (of a hypothetical char-
acter who succeeded in quitting smoking) were significant in the analysis reported in
[88]. For simplicity, we considered only these two treatment factors at stage 1 of our
present analysis, which gave a total of 4 treatment combinations at stage 1 corre-
sponding to the 2× 2 design. The treatment factor source was varied at two levels,
e.g., high vs. low personalized, coded 1 and −1; also the factor story was varied at
two levels, e.g., high vs. low tailoring depth (degree to which the character in the
story was tailored to the individual subject’s baseline characteristics), coded 1 and
−1. We considered only a few baseline variables at this stage, e.g. QuitOverallMotiv
(motivation to quit on a 1-10 scale), QuitOverallSE (self-efficacy on a 1-10 scale)
and Education (binary, ≤ high school vs. > high school, coded −1/1). At stage
2, originally there were 4 different treatment groups and a control group; however
the 4 treatment groups were combined together for the present analysis because of
very little difference between them. This resulted in only two choices of treatment at
stage 2; this treatment variable was called FFArm, coded −1/1 (1=treatment, −1 =
control).
There were two outcomes at the two stages of this study. The stage 1 outcome was
binary quit status called PQ6Quitstatus (1=quit, 0=not quit) at 6 month from the
date of randomization. The stage 2 outcome was binary quit status FF6Quitstatus
at 6 months from the date of stage 2 randomization (i.e., 12 months from the date
of stage 1 randomization).
An example DTR can have the following form: “At stage 1, if a subject’s baseline
self-efficacy is greater than a threshold value (say 7, on a 1-10 scale), then provide the
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highly-personalized level of the treatment component source, and if the subject is
willing to continue treatment, then at stage 2 provide treatment if s/he continues to
be a smoker at the end of stage 1”. Of course characteristics other than self-efficacy
or a combination of more than one subject characteristics can be used to specify a
DTR. To find the optimal DTR, we applied both the hard-max and the soft-threshold
estimators within the Q-learning framework. This involved: (1) a stage 2 regression
(n = 281) of FF6Quitstatus using the model:
FF6Quitstatus = β20 + β21 QuitOverallMotiv + β22 source + β23 QuitOverallSE
+ β24 story + β25 Education + β26 PQ6Quitstatus
+ β27 source ∗QuitOverallSE + β28 story ∗ Education
+
(
ψ20 + ψ21 PQ6Quitstatus
)
∗ FFArm + ε2;
(2) finding both the hard-max pseudo-outcome (Ŷ1) and the soft-threshold pseudo-
outcome (Ŷ ST1 ) for the stage 1 regression:
Ŷ1 = PQ6Quitstatus + β̂20 + β̂21 QuitOverallMotiv + β̂22 source
+ β̂23 QuitOverallSE + β̂24 story + β̂25 Education + β̂26 PQ6Quitstatus
+ β̂27 source ∗QuitOverallSE + β̂28 story ∗ Education
+
∣∣∣ψ̂20 + ψ̂21 PQ6Quitstatus
∣∣∣;
Ŷ ST1 = PQ6Quitstatus + β̂20 + β̂21 QuitOverallMotiv + β̂22 source
+ β̂23 QuitOverallSE + β̂24 story + β̂25 Education + β̂26 PQ6Quitstatus
+ β̂27 source ∗QuitOverallSE + β̂28 story ∗ Education
+
∣∣∣ψ̂20 + ψ̂21 PQ6Quitstatus
∣∣∣ ·
(
1− 3Var(ψ̂20 + ψ̂21 PQ6Quitstatus)|ψ̂20 + ψ̂21 PQ6Quitstatus|2
)+
;
and (3) for each of the two pseudo-outcomes, a stage 1 regression (n = 1401) of the
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pseudo-outcome using a model of the form:
Ŷ1 or Ŷ
ST


















∗ story + ε1.
Note that the sample sizes at the two stages differ because only 281 subjects were
willing to continue treatment into stage 2 (as allowed by the study protocol). Our
stage 2 analysis was a usual regression analysis. No significant treatment effect was
found at this stage, indicating the likely existence of non-regularity. At stage 1,
for either estimator, 95% confidence intervals were constructed by hybrid bootstrap
using 1000 bootstrap replications. The stage 1 analysis summary is presented in
Table 5.4. In this case, the hard-max and the soft-threshold estimators produced
similar results.
Table 5.4: Regression coefficients and 95% hybrid bootstrap confidence intervals at stage 1, using
both the hard-max and the soft-threshold estimators.
Hard-max Soft-threshold
Variable Coefficient 95% CI Coefficient 95% CI
QuitOverallMotiv 0.04 (-0.00, 0.08) 0.04 (0.00, 0.08)
QuitOverallSE 0.03 (0.00, 0.06) 0.03 (0.00, 0.06)
Education -0.01 (-0.07, 0.06) -0.01 (-0.07, 0.06)
source -0.15 (-0.35, 0.06) -0.15 (-0.35, 0.06)
source*QuitOverallSE 0.03 (0.00, 0.06) 0.03 (0.00, 0.06)
story 0.05 (-0.01, 0.11) 0.05 (-0.01, 0.11)
story*Education -0.07 (-0.13, -0.01) -0.07 (-0.13, -0.01)
The conclusions from the present data analysis can be summarized as follows.
We did not find any significant stage 2 treatment effect. So this analysis suggests
that the stage 2 behavioral intervention need not be adapted to the smoker’s indi-
vidual characteristics, interventions previously received, or stage 1 outcome. More
interesting results are found at stage 1. It is found that subjects with higher level
of motivation or self-efficacy are more likely to quit. The highly personalized level
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Figure 5.2:
Interaction plots: (a) source by self-efficacy (left panel), (b) story by education (right
panel), along with confidence intervals for predicted stage 1 pseudo-outcome.
of source is more effective for subjects with a higher self-efficacy (≥ 7), and deeply
tailored level of story is more effective for subjects with lower education (≤ high
school); these two conclusions can be drawn from the interaction plots (with confi-
dence intervals) presented in figure 5.2. Thus this analysis suggests that to maximize
each individual’s chance of quitting over the two stages, the web-based smoking ces-
sation intervention should be designed in future such that: (1) smokers with high
self-efficacy (≥ 7) are assigned to highly personalized level of source, and (2) smok-
ers with lower education are assigned to deeply tailored level of story.
5.5.2 Analysis using Multiple Imputation
As mentioned in chapter II, the study started with 1848 subjects (Project Quit),
out of which 479 consented to move to stage 2 (Forever Free). Among these, there
were 1401 complete cases at stage 1 and 281 complete cases in stage 2, and were
included in the complete-case analysis presented above. The completely observed
variables (X) in the study were: HMO (binary), gender (binary), age (continuous),
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QuitCigsPerDay (baseline number of cigarettes smoked per day, continuous), and
the five stage-1 treatment components, e.g., source (personalization of source),
outcome.depth (tailoring depth of outcome expectations), story (tailoring depth
of success stories), efficacy.depth (tailoring depth of efficacy expectations), and
exposure – each with 2 levels. The remaining variables (Y) along with their miss-
ingness rates are listed below.
Table 5.5: Baseline Variables subject to Missingness
Variables Number of Rate of
Missing Values Missingness (%)
QuitOverallMotiv (motivation, 1-10, continuous) 5 0.27
QuitOverallSE (self-efficacy, 1-10, continuous) 4 0.21
Education (binary, high school vs. college) 7 0.38
RaceWhite (binary, 1 if the subject is White) 10 0.54
RaceBlack (binary, 1 if the subject is Black) 10 0.54
The variables RaceWhite and RaceBlack are two dummy variables constructed
from the original three-level variable Race. The rates of missingness are very small
in the baseline variables. Below we list the missingness rates of the stage-1 variables.
Table 5.6: Stage-1 (collected at 6 months) Variables subject to Missingness
Variables Number of Rate of
Missing Values Missingness (%)
PQ6Quitstatus (binary, 1= quitter, 0=smoker) 436 23.59
PQ6MonthsNS (months not smoked, 0-6) 699 37.82
PQ6OverallSat (overall satisfaction, 1-10) 439 23.76
PQ6NumOfAttempts (number of quit attempts) 656 35.50
PQ6OverallMotiv (motivation, 1-10) 440 23.81
PQ6OverallSE (self-efficacy, 1-10) 442 23.92
Next we discuss our strategy to model different variables for the purpose of
multiple imputation. The variables PQ6OverallMotiv (and QuitOverallMotiv),
PQ6OverallSE (and QuitOverallSE) and PQ6OverallSat are all left-skewed and
vary in the range 1 − 10; for convenience of modeling we binarize them (cutting
off at the respective means leading to two levels, high vs. low). The corresponding
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binarized variables go by the same name as the original variable, except for the suffix
Bin. Histograms of the remaining stage-1 variables are presented below.
Figure 5.3: Histograms of PQ6Quitstatus, PQ6MonthsNS, and PQ6NumOfAttempts.
From the histograms above, we see that:
1. PQ6MonthsNS cannot be modeled by a normal distribution; a better modeling
strategy would be to use 6 dummy variables to represent it, each of which will
be approximated by a normal and then rounded off.
2. PQ6NumOfAttempts is right-skewed; a square-root transformation may be better
(see below).
Next, let us look at the stage-2 variables. Among the 479 subjects who moved to
stage 2 (Forever Free), the stage-2 treatment, FFArm (2 levels) is completely observed.
Below we list the missingness rates (out of 479 subjects) of the stage-2 variables.
Clearly, the rates of missingness are pretty high at stage 2. As in stage 1, we
binarize the variable denoting the level of satisfaction with the smoking cessation
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Figure 5.4: Histograms of PQ6NumOfAttempts and its square-root.
Table 5.7: Stage-2 (collected at 12 months) Variables subject to Missingness
Variables Number of Rate of
Missing Values Missingness (%)
FF6Quitstatus (binary, 1= quitter, 0=smoker) 195 40.71
FF6MonthsNS (months not smoked, 0-6) 264 55.11
FF6OverallSat (overall satisfaction, 1-10) 205 42.80
FF6NumOfAttempts (number of quit attempts) 263 54.91
program (FF6OverallSat). Let us look at the histograms of the remaining stage-2
variables. From the histograms, we see that:
1. FF6MonthsNS clearly cannot be modeled by a normal distribution. As in stage
1, the first alternative strategy would be to use 6 dummy variables to represent
the original variable, and approximate each dummy variable by a normal dis-
tribution and then round off. However, note that the frequency corresponding
to some of the levels (e.g. 3, 4, 5) are really small, making the success prob-
abilities of the corresponding dummies very small – a situation where normal
approximation fails to do a good job [4]. To address this issue, the variable is
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Figure 5.5: Histograms of FF6Quitstatus, FF6MonthsNS, and FF6NumOfAttempts.
re-coded with only three levels, 0, 1, and 2: it takes the value 0 if the original
FF6MonthsNS is 0, takes the value 1 if 0<FF6MonthsNS<=3, and takes the value
2 if 3<FF6MonthsNS<=6. For consistency among the stages, the corresponding
stage-1 variable, PQ6MonthsNS is also re-coded accordingly.
2. FF6NumOfAttempts is right-skewed; a square-root transformation may be some-
what better although not completely satisfactory (see below).
Next let us examine the histograms of the newly constructed outcome variables
(trinary version of PQ6MonthsNS and FF6MonthsNS).
Since PQ6MonthsNS is sort of symmetric and unimodal (and of course ordinal),
instead of breaking it into two dummies, it is directly modeled by a normal distribu-
tion and then rounded off. On the other hand, FF6MonthsNS is modeled using two
dummies, using a normal approximation for each.
We used multiple imputation under a multivariate normal model (see Appendix
C). The MCMC procedure for MI converged nicely with the default non-informative
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Figure 5.6: Histograms of FF6NumOfAttempts and its square-root.
priors. A burn-in period of 1000 iterations was used in the MCMC procedure. The
following graph provides a global check of convergence of the MCMC – the auto-
correlation function of the “worst cosine function” as described by Schafer [80]. Even
Figure 5.7: Histograms of PQ6MonthsNS and FF6MonthsNS (trinary).
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though in most cases the convergence of the above global criterion ensures conver-
gence of the individual parameters, there is no theoretical guarantee (and there exist
counterexamples). None-the-less, it is a good starting point to assess the convergence
of the MCMC procedure.
Figure 5.8: Auto-correlation function of the worst cosine function.
Next we present some checks for the individual parameters of interest, e.g. the re-
gression parameters associated with the variables PQ6MonthsNS, FF6MonthsNSDummy1
and FF6MonthsNSDummy2, since these will be considered as the primary outcome vari-
ables in the data analysis to follow.
Next we present the actual analysis of the multiply imputed data set. The point
estimates (regression coefficients in the Q-learning analysis) reported here are av-
erages of the corresponding coefficients over 10 imputed data sets. Measures of
confidence are provided by bootstrap CIs. We use 500 bootstrap samples, and 10
imputations within each bootstrap sample. Within a given bootstrap sample, the
regression coefficients in the model for Q-functions are created by averaging over 10
imputed datasets. Finally, the quantiles of these bootstrapped coefficients (each one
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Figure 5.9: Auto-correlation functions of the regression parameters associated with the stage-1 out-
come (PQ6MonthsNS).
Figure 5.10: Auto-correlation functions of the regression parameters associated with the first
dummy variable corresponding to the stage-2 outcome (FF6MonthsNSDummy1).
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Figure 5.11: Auto-correlation functions of the regression parameters associated with the second
dummy variable corresponding to the stage-2 outcome (FF6MonthsNSDummy2).
is an average over 10 imputations) are used to create the hybrid bootstrap CIs.
Here we use a very parsimonious analysis model, with story as the only stage-1
treatment variable, Education as the only stage-1 covariate, and PQ6Quitstatus as
the only stage-2 covariate. The outcome variables are PQ6MonthsNS (stage 1) and
FF6MonthsNS (stage 2), both taking values 0, 1, 2. The stage-2 regression model
(n = 479) is given by:
FF6MonthsNS ∼ story + Education + PQ6Quitstatus +
story ∗ Education + FFArm + PQ6Quitstatus ∗ FFArm
Based on the estimated coefficients of the stage-2 regression, both the hard-max and
the soft-threshold pseudo-outcomes are constructed (as in section 5.5.1). Then the
stage-1 regression model (n = 1848) is given by:
Pseudooutcome ∼ story + Education + story ∗ Education
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No significant stage-2 treatment effect was found (consistent with the complete case
analysis), indicating the likely existence of non-regularity. Results of the stage-1
regression analysis is presented below.
Table 5.8: Regression coefficients and 95% hybrid bootstrap confidence intervals at stage 1, using
both the hard-max and the soft-threshold estimators, and using multiple imputation.
Hard-max Soft-threshold
Variable Coefficient 95% CI Coefficient 95% CI
Education 0.011 (-0.180, 0.199) 0.012 (-0.178, 0.200)
story 0.072 (-0.074, 0.195) 0.070 (-0.076, 0.192)
story*Education -0.112 (-0.240, -0.004)* -0.111 (-0.237 -0.002)*
Next we present the lengths of the bootstrap CIs for the two competing methods
of estimation; the soft-threshold method looks marginally better.





In Table 5.8, a negative interaction between story and Education is detected.
This is one of the interactions anticipated a priori by the study investigators; see [88].
This finding is also consistent with the complete case analysis in section 5.5.1. This
negative interaction is interpretable – it says that highly individually tailored level of
story (success story of a hypothetical smoker) is significantly more effective within
smokers with low education (high school graduate or less, but no college education).
This finding allows one to individually tailor the smoking cessation intervention.
5.6 Discussion
In this chapter, we have illustrated the problem of non-regularity that arises in the
context of DTRs in the estimation of the optimal current treatment rule, when the
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optimal treatments at subsequent stages are non-unique for at least some proportion
of subjects in the population. We have illustrated the phenomenon using Q-learning
as the estimation procedure, which is a simpler yet inefficient version of Robins’
method; however the problem of non-regularity arises in Robins’ method as well
[71, 54].
For some underlying data-generating models (e.g., Examples 3, 4, 5 in the simula-
tion study), this non-regularity induces bias in the point estimates of the parameters
of the optimal DTRs, which in turn causes under-coverage of the bootstrap confi-
dence intervals. In contrast, in case of Examples 1 and 2, this non-regularity causes
lightness of tail of the asymptotic distribution but no bias, as seen from the over-
coverage of the percentile bootstrap CIs (equivalently conservative tests leading to
lower power). The coexistence of these two not-so-well-related issues (they work in
opposite directions, e.g., bias tends to make the CIs under-cover, whereas lightness of
tail tends to make the CIs over-cover) makes this problem a unique and challenging
one.
In the simulation study to compare the competing estimators of the optimal DTR,
we considered estimation of ψ10, which involve linear combinations of |f1|, |f2|, |f3|,
and |f4| (terms like |µ|). Under the non-regular scenarios, some or all (depending
on the degree of non-regularity p) of the fi’s are zero; and hence a phenomenon
similar to the one described above in the toy example happens for each |fi| for which
fi = 0. Each such term has its associated bias, and each has its own lightness of tail,
with bias being the dominant property. In some non-regular scenarios (Example 1),
the bias associated with the individual |fi|’s (in the expression for ψ10) cancel each
other out (note the opposite signs in front of |fi|’s), and hence the lightness of tail is
revealed, resulting in a percentile bootstrap CI that over-covers. In other non-regular
134
examples, however, bias is not canceled out, and hence dominates the property of
the hard-max estimator. Hence under-coverage of the bootstrap CIs is observed.
Non-regularity is an issue in the estimation of the optimal DTRs because it arises
when there is no treatment effect at subsequent stages (equivalently, there is no
unique optimal treatment at subsequent stages). Unfortunately often there is no
or very weak treatment effect in the settings we are interested in (e.g., random-
ized trials on mental illness or substance abuse). Thus we want our estimator to
enjoy good statistical properties (e.g., less bias, lower risk or MSE, correct cover-
age rate of CIs, good power to detect “local” alternatives, etc.) when the optimal
treatment at subsequent stages is non-unique. In case of the hard-max estimator,
unfortunately the point of non-differentiability coincides with the parameter value
such that ψT2 H21 = 0 (non-unique optimal treatment at the subsequent stage), which
causes non-regularity (bias, higher MSE, low power). But the soft-threshold estima-
tor (also, hard-threshold estimator), in some sense, redistributes the non-regularity
from this “null point” to two different points symmetrically placed on either side of
the “null point” (see Figure 5.1). This is one reason why the soft-threshold (also,
hard-threshold) estimator works well in non-regular settings.
We have shown that using bootstrap confidence intervals along with the soft-
threshold (also, hard-threshold in some cases) estimator reduces the degree of non-
regularity, and gives correct coverage rate. Also, the double bootstrap method can
be used along with the original hard-max estimator to address the non-regularity.
But this method is highly computationally intensive and may be difficult to use in
practice. An alternative method to construct CIs for ψ’s in non-regular settings is
the score method due to Robins [71]. We have not investigated this in our simulation
study.
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One can consider an alternative Bayesian approach to formulate an estimator simi-
lar to the soft-threshold estimator as follows. Let the data distribution ψ̂T2 H21 | ψT2 H21 ∼
N(ψT2 H21, σ
2) with known σ2, and the prior distribution of ψT2 H21 be a mixture of
a point mass at 0 and N(0, 1), with mixing parameter p (0 < p < 1). Then the
posterior distribution of ψT2 H21 is a mixture distribution given by
fpost(ψ
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One can use the median of this posterior distribution in place of ψ̂T2 H21 in the ex-
pression for Ŷ1. Thus the Bayes estimator becomes
Ŷ Bayes1 = β̂
T
2 H20 + median of fpost(ψ
T
2 H21).
For using this, one has to replace σ2 by σ̂2 = HT21Σ̂2H21/n, and p by either some
empirical estimate or a fixed value (e.g., 1
2
). Johnstone and Silverman [46] suggest
using the mixture of a point mass and a heavy-tailed distribution (e.g., double-
exponential) in place of the above mixture prior. This is a formulation that we want
to investigate in future. Also, fully Bayesian approaches to handle the problem of
estimating DTRs demand serious attention; we will consider this in future.
In this chapter, we have focused on randomized trials only to separate the issue of
non-regularity from causal inference issues. However the problem of non-regularity
also arises when observational data are used [71, 54]; and the hard-threshold and the
soft-threshold estimators should be applicable in those settings as well. Also, here
we have focussed on only two stages for clarity. However, it should be understood
that Q-learning can be used for studies with more than two stages as well. In case of
many stages, one can think of a scenario where some parameters are shared across
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stages, in which case a simultaneous version of Q-learning (as opposed to the recursive
version discussed in this chapter) would be more appropriate. Unfortunately non-
regularity does not go away if a simultaneous estimation procedure is used; see [54]
for a discussion on this with reference to Robins’ method. However, unlike the case
of recursive estimation, it is not well understood at this point whether the threshold
estimators (hard or soft) can reduce the non-regularity in simultaneous estimation.
Moodie and Richardson [54] gave a simulated non-regular example showing that
hard-threshold or ZIPI estimator is not always better than simultaneous estimator of
Robins. We did not investigate this issue here, but we recognize this as an important
avenue of future research.
To conclude, we think in the estimation of optimal DTRs, appropriately tuned
hard-threshold estimator and the soft-threshold estimator should be seriously con-
sidered as improved versions of Q-learning (and Robins’ method of estimation).
5.7 Appendix A: Proof of Lemma V.1
Proof. Define the advantage at stage j as
µj(Hj, Aj) = Qj(Hj, Aj)−max
aj
Qj(Hj, aj), j = 1, 2.
Note that µj(Hj, Aj) represents the expected difference in outcome when using Aj
instead of the optimal treatment at stage j, for subjects with treatment and covariate
history Hj who receive the optimal DTR at stages subsequent to j. According to
Robins [71, p. 201], this is simply the blip function with arg maxaj Qj(Hj, aj) as the
reference treatment. Below we will establish the connection between Q-learning and
Robins’ method using the advantage function; one can derive the connection using
other blip functions (other choices of reference treatment) following similar steps.
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When Q-functions are modeled as in (5.2), the advantages become
µj(Hj, Aj; ψj) = ψ
T
j Hj1Aj − |ψTj Hj1|, j = 1, 2.(5.11)
Since by condition (i), no parameters are shared across stages, we will proceed stage
by stage, starting with stage 2, doing recursive (rather than simultaneous) estimation.
The notation Pn will be used below to denote the empirical average over a sample
of size n. Also, define m1(H1) = E[Q1(H1, A1)|H1] and m2(H2) = E[Q2(H2, A2)|H2].
Stage 2:
At stage 2, Q-learning is a usual least squares regression problem. Thus the estimat-
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= 0.(5.12)


























Y2−µ2(H2, A2; ψ2)−E[Y2−µ2(H2, A2; ψ2)|H2]
∣∣∣H2, A2
)
is omitted (This is
one of the reasons why Q-learning is an inefficient version). Note that E[H21A2|H2] =
0, by condition (ii) of the lemma. From (5.11), µ2(H2, A2; ψ2) = ψ
T
2 H21A2−|ψT2 H21|.





= E[Q2(H2, A2)|H2] = m2(H2).
Therefore, Y2−µ2(H2, A2; ψ2)−E[Y2−µ2(H2, A2; ψ2)|H2] = Y2−m2(H2)−HT21A2ψ2.








for any choice of m2(H2) (with the conditional variance omitted). In particular,
for m2(H2) = H
T
20β̂2, where β̂2 is given by (5.13), this estimating equation exactly
matches with that of Q-learning.
Stage 1:
For Q-learning, the stage 1 pseudo-outcome is
Ŷ1 = Y1 + max
a2
Q2(H2, A2) = Y1 + H
T
20β̂2 + |ψ̂T2 H21|,
























Since by condition (iii) of the lemma, (HT10, H
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Y1 + Y2 −HT21A2ψ̂2 + |ψ̂T2 H21| −HT10β̂1 −HT11A1ψ̂1
)]
= 0.
On the other hand for Robins’ method, the stage 1 pseudo-outcome (e.g. [71, p. 208];
see also [54]) is Ỹ1 = Y1 + Y2 − µ2(H2, A2), and so the stage 1 estimating equation









where again the conditional variance
V ar
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is omitted. Note that E[H11A1|H1] = 0, by condition (ii) of the lemma. From (5.11),
µ1(H1, A1; ψ1) = ψ
T
1 H11A1−|ψT1 H11|. Then E[µ1(H1, A1; ψ1)|H1] = −|ψT1 H11|, again
by condition (ii). Also,
E[Ỹ1|H1] = E[Y1 + Y2 − µ2(H2, A2)|H1]





E[Y −Q2(H2, A2)|H2, A2]
∣∣∣H1
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+ E[Y1 + max
a2
Q2(H2, a2)|H1]









Finally, plug in Y1 + Y2 − µ2(H2, A2; ψ̂2) for Ỹ1. Thus, ψ̂1 in Robins’ method solves





Y1 + Y2 −HT21A2ψ̂2 + |ψ̂T2 H21| −m1(H1)−HT11A1ψ̂1
)]
= 0.
for any choice of m1(H1) (again omitting the conditional variance). In particular,
for m1(H1) = H
T
10β̂1, where β̂1 is given by (5.19), this estimating equation exactly
matches with that of Q-learning.
In summary, the Q-learning algorithm as presented here is inefficient because: (a)
it sets the conditional variances to be constant over (Hj, Aj), and (b) uses Hj1Aj in-
stead of the “efficient choice” of the term Seff,j (that attains semiparametric variance
bound) in Robins’ estimating equation (see [71, p. 212]; more details in [70]).
5.8 Appendix B: Proof of Lemma V.2
Proof. To estimate the hyper-parameter φ2, first integrate out µ to get the marginal
likelihood X|φ2 ∼ N(0, φ2 + σ2). The corresponding Jeffrey’s prior on the vari-
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ance parameter is p(φ2) ∝ 1/(φ2 + σ2). Based on this formulation, the posterior
distribution of φ2 is given by







Hence the posterior mode of φ2 is









Given φ2 = φ̂2, now we will consider the data likelihood X|µ ∼ N(µ, σ2) along with
the prior µ|φ2 ∼ N(0, φ2) to derive an empirical Bayes estimator for |µ|. It is easy
to show that the posterior distribution of µ given φ = φ̂ is









Now under the squared error loss, the Bayes estimator of |µ| is Eµ|X(|µ|) which can
be calculated using (5.22). If Y ∼ N(θ, τ 2), then E|Y | is given by:










In the present problem,
Y = µ|X, θ = Xφ̂
2
φ̂2 + σ2














































































































5.9 Appendix C: A Very Brief Review of Multiple Imputation
Multiple imputation (MI) [75] is a simulation-based Bayesian approach to handle
missing data. The basic idea is to solve an incomplete-data problem by repeat-
edly, say m(> 1) times, solving a corresponding complete-data problem, and finally
combining (averaging) them. The different imputations are conceived as indepen-
dent draws from a posterior predictive distribution for the missing data, given the
observed data. The variation among the m imputations reflect the uncertainty in
predicting the missing values from the observed ones. A single imputation cannot
capture this uncertainty; this is why MI is generally considered a better missing data
technique than single imputation.
Generally speaking, MI operates by assuming a model for the complete multivari-
ate data and also assuming certain priors for the parameters of the multivariate data
model. It is found that even though one assumes parametric models, the procedure
is considerably robust to mis-specification of the complete data model, particularly
if the “rate of missingness” is not very high. This is, at least partly, due to the fact
that the mis-specification, if any, applies only to the missing part of the data, and
not to the entire data (as in the EM algorithm). While analyzing data, one can
use an analysis model that is quite different from the imputation model. Thus, the
mis-specifications of the imputation model do not necessarily carry over to the data
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analysis model. The MI procedure is often implemented via Markov Chain Monte
Carlo (MCMC) techniques. However the MI procedure is still not very demanding
computationally, since only a few (say, 5−10) imputations are usually good enough.
See [79] for further discussion.
To make the above discussion more precise, let us introduce some notation. Let
the complete data Y be partitioned into an observed part (Yobs) and a missing part
(Ymis), e.g., Y = (Yobs, Ymis). Let R denote the indicator of response (or equivalently,
missingness). Let θ denote the parameters of the data model and ξ denote the
parameters governing the missingness mechanism (e.g., the distribution of R). In
this set-up, ignorability of the missingness mechanism means the following:
1. The data are missing at random (MAR), i.e., P (R|Yobs, Ymis, ξ) = P (R|Yobs, ξ);
2. The parameters θ and ξ are a priori independent.
We will assume ignorability throughout. As mentioned earlier, an imputation is a
random draw from the posterior predictive distribution for the missing data, given
the observed data:
(5.25) P (Ymis|Yobs) =
∫
P (Ymis|Yobs, θ)P (θ|Yobs)dθ
Note that the above is an intractable integral over θ; moreover P (θ|Yobs) itself is an
intractable integral over Ymis. However it is relatively straightforward to sample from
θ|(Yobs, Ymis) and Ymis|(Yobs, θ). Thus to overcome the intractability of (5.25), one
uses an MCMC sampling scheme to generate a draw from Ymis|Yobs. The procedure
is known as data augmentation [92], which is a close variant of Gibbs sampling. The
algorithm follows:
1. Start with an initial guess for θ, say θ(0)
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2. At the (t + 1)-th iteration, t = 0, 1, 2, . . .,
Y
(t+1)
mis ∼ Ymis|Yobs, θ(t),
θ(t+1) ∼ θ|Yobs, Y (t+1)mis .
3. After a large number of iterations (e.g. the burn-in period), Ymis drawn this
way can be taken as a draw from the true target distribution P (Ymis|Yobs).
Note that the successive draws from the Markov chain will be correlated. To over-
come this, the successive imputations should be far apart in the chain. See [79] for
further details.
Imputations under a Multivariate Normal Model
Often imputations are done assuming a multivariate normal distribution for the
complete data Y , e.g., Np(µ, Σ) (thus θ = (µ, Σ) in this case), where p is the dimen-
sion of Y . The conjugate prior for this family is normal for µ and inverted-Wishart
for Σ (together called the normal inverted-Wishart prior). It is given by
µ|Σ ∼ Np(µ0, τ−1Σ),
Σ ∼ W−1(m, Λ),
for fixed hyper-parameters µ0 ∈ Rp, τ > 0, m ≥ p, and Λ > 0. However when no
strong prior information is available about θ, it is customary to use the improper
prior
(5.26) π(θ) ∝ |Σ|−( p+12 ),
which is the limiting form of the normal inverted-Wishart prior as τ →∞, m → −1
and Λ−1 → 0. Note that µ does not appear on the right side of (5.26); the prior
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distribution of µ is assumed to be uniform over the p-dimensional real space. Under
this improper prior, the complete-data posterior becomes
µ|Σ, Y ∼ Np(Ȳ , n−1Σ),
Σ|Y ∼ W−1(n− 1, (nS)−1),
where S is the sample sums of squares and cross-products matrix. See [79] for further
details.
Conditional Modeling
When some of the variables in a data set are completely observed, a better impu-
tation strategy is to use them simply as covariates (denoted by X, say) and assume
a multivariate model for the remaining variables that are subject to missingness,
say Y conditionally on X. By following this strategy, one relaxes the assumption
of normality for the completely observed covariates, thus lowering the risk of model
mis-specification. This means that the data model becomes yi|xi ∼ N(βT xi, Σ), with
the noninformative improper prior for β and inverted-Wishart prior for Σ. Here i
denotes a certain row in the data set (i = 1, . . . , n). This modeling strategy is al-
lowed by the R package NORM Version 3, developed by Schafer [80].
Normal Modeling for Non-normal Data
Sometimes multiple imputations are conducted assuming a joint normal distribu-
tion for the data, even when there are some binary, categorical or ordinal variables
in the data set [79]. In such cases, imputed values of binary or ordinal variables are
rounded or classified after imputation to get a sensible imputed data set. Using a
normal model for a categorical variable needs special consideration; one reasonable
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strategy is to first convert the categorical variable into several binary variables, use
a normal approximation for each of them, and then round off the value to make it
binary (after imputation). Robustness of such model mis-specifications was studied
by Bernaards et al. [4].
Our smoking cessation data set contains binary, categorical and ordinal variables
along with continuous variables. None-the-less we used the multivariate normal
modeling because of its conceptual simplicity, ready availability of software and its
allowance of conditional modeling. We used some ad hoc but sensible strategies
[79, 80, 4] to make post-imputation adjustments (rounding, classification etc.).
CHAPTER VI
Future Work and Conclusion
This dissertation explores two research projects, e.g. the problem of designing
multicomponent intervention trials, and the problem of non-regularity in the dy-
namic treatment regime framework. Each of these projects investigated in the pre-
vious chapters has its own direction; each raise new and challenging questions and
opens up possibilities for further research. In the following we briefly discuss some
of these problems that we plan to explore in greater depth in future.
6.1 Follow up Studies for Multicomponent Interventions
In Chapter III, we discussed the usefulness of FFDs in screening trials for de-
veloping multicomponent interventions. However, screening study is only the first
phase of the MOST framework. Depending on the aliasing pattern of the screening
design used, one often needs to conduct follow-up or refining studies to resolve any
remaining research questions regarding the various components and their interactions
(e.g. to de-alias significant aliased interactions) after the completion of the screening
study. In Chapters III and IV, we provided some examples of follow-up studies.
However some principled approach needs to be developed in this area. For example,
some Bayesian approach, where one puts suitable priors on the effects of various
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components and interactions, might be useful for designing follow-up studies. Such
an approach can be found in [52]. Further strategies for conducting follow-up studies
can be found in [107]. Also, in case there is at least one component with more than
two levels (e.g. a continuous component), dose-response experiments where subjects
are randomized to ethical doses should be used to find the optimal dose of these com-
ponents. The existing literature on response surface experiments [10, 61] may prove
useful for finding designs applicable to the multicomponent intervention setting. We
would like to explore these areas to develop efficient follow-up study designs in future.
6.2 Soft-threshold Estimator for More than Two Treatments per Stage
In Chapter V, we discussed the soft-threshold estimator in the context of Q-
learning. However, we assumed only two treatment options per stage all along. A
natural question that arises here is how to generalize this estimator in the setting of
more than two treatments per stage. We do not have a direct answer at this point.
Recall that the problem of non-regularity occurs due to a non-smooth maximum
operation, e.g. maxa Q2(H2, a). When the Q-functions are linear (as in this disserta-
tion), maximization over a binary a gives rise to a piecewise linear function with only
one hinge or point of non-differentiability (see Chapter V for details). When there
are more than two treatments per stage, i.e., when a takes more than two values,
maxa Q2(H2, a) will be a piecewise linear function with possibly more than one point
of non-differentiability.
Now in case of two treatments per stage, the soft-threshold estimator works by
thresholding this piecewise linear function around its point of non-differentiability.
To extend this idea to the multi-treatment case, one would like to somehow threshold
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the function maxa Q2(H2, a) around each of its points of non-differentiability. Note,
however, that it is not even clear what thresholding means in such a scenario. Even
when thresholding has some meaning, it is not clear how to choose the multiple tun-
ing parameters, one for each point of non-differentiability. If one takes recourse to a
Bayesian approach, some suitable multivariate prior needs to chosen. This, clearly, is
a non-trivial problem; some serious thought is needed. We would like to investigate
this in future.
6.3 Consistent Bootstrap Procedure for Non-regular Settings
It is well-known [84, 2] that the usual bootstrap procedure is inconsistent for
non-regular (non-differentiable) settings. Note that even though the threshold esti-
mators (both hard and soft) empirically seemed to perform better than the original
hard-max estimator (see Chapter V), both the hard-threshold and the soft-threshold
estimators are non-regular (as is the original hard-max estimator). Hence the valid-
ity of usual bootstrap CIs for threshold estimators is not theoretically justified. A
nice theoretical project would be to develop a consistent bootstrap procedure, e.g.
some “adaptive” version of the usual bootstrap, to use in conjunction with the soft-
threshold estimator. We would like to explore this in future.
6.4 Concluding Remarks
This dissertation investigated two broad problems with practical relevance to clin-
ical trials and medical statistics. “Evidence-based” treatments (treatment sequences)
are of great interest in the behavioral sciences and in medicine; our research is an
ongoing endeavor to address that interest. In particular, the area of dynamic treat-
150
ment regimes is very young and exciting; and there are many interesting problems
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